Protocol H9X- MC-B021(b) 
 
Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) P en 
 NCT 03724981 
 Approval Da te: 30-Nov-2018 
H9X-MC-B021(b) Clini calProtocol Page 1
LY2189265Approval Date: 30 -Nov-2018 GMTProtocol H9X -MC-B021 (b): Crossover Study Comparing the 
Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_81058] (LY2189265) , unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries .
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercia lly confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Dulaglutide (LY2189265 )
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by[CONTACT_454848]
07 Aug 2018
Amendm ent (a) Electronically Signed and Approved by [CONTACT_229490]
11 Sep 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_731757]
H9X-MC-B021(b) Clini calProtocol Page 2
LY2189265Table of Contents
Section Page
Protocol  H9X -MC-B021(b):  Crossover Study  Comparing the Dulaglut ide 
(Trulicit y) Pen and the Semaglut ide (Ozempic) Pen ............................................................ [ADDRESS_999520] ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 14
3.1. Study  Rati onale ............................................................................................................ 14
3.2. Background .................................................................................................................. 15
3.2.1. Dulaglut ide Pen .................................................................................................... 15
3.2.2. Semaglut ide Pen ................................................................................................... 16
3.3. Benefit/Risk Assessment .............................................................................................. 17
3.4. Risks and Foreseeable Adverse Events/Device Effects ................................................. [ADDRESS_999521] ion Process ................................................................................................ 22
5.5.1. Pi[INVESTIGATOR_42751]:  Participant Recruit ment and Screening 
Procedures ........................................................................................................... 23
5.5.2. Main Phase:  Participant Recruit ment and Screenin g 
Procedures ........................................................................................................... 23
5.5.3. Overview of Study  Visi t Procedures for the Pi[INVESTIGATOR_42751] ....................................... 24
5.5.4. Overview of Study  Visi t Procedures for the Main Phase ....................................... 26
5.6. Justification for Dose ................................................................................................... 27
6. Study  Popul ation............................................................................................................... 28
6.1. Inclusio n Cri teria.......................................................................................................... 28
6.2. Exclusio n Cri teria........................................................................................................ 28
6.3. Screen Failures ............................................................................................................. 29
7. Treatments ........................................................................................................................ 30
7.1. Treatment s Administered ............................................................................................. 30
7.1.1. Packaging and Labeling ....................................................................................... 30
H9X-MC-B021(b) Clini calProtocol Page 3
LY21892657.1.2. Medical Devices ................................................................................................... 30
7.2. Method of Device Assignment ..................................................................................... 30
7.2.1. Selection and Timing o f Doses ............................................................................. 31
7.3. Blinding ....................................................................................................................... 31
7.4. Dosage Modification .................................................................................................... 31
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_999522] to Follow -Up........................................................................................................ 33
9. Study  Assessments and Procedures ................................................................................... 34
9.1. Outcom e Assessments .................................................................................................. 34
9.1.1. Primary/Secondary Assessments .......................................................................... 34
9.1.2. Appropriateness of Assessments .......................................................................... 34
[IP_ADDRESS]. Suppl emental  Quest ions................................................................................. 34
[IP_ADDRESS]. Time -to-Train Observer Recording Sheet ....................................................... 34
[IP_ADDRESS]. Dem ographic Form ......................................................................................... 35
[IP_ADDRESS]. Interviewer Recording Sheet ........................................................................... 35
[IP_ADDRESS]. Pi[INVESTIGATOR_731695]...................................................................... 35
[IP_ADDRESS]. Global Preference Item ................................................................................... 35
[IP_ADDRESS]. Diabetes Inject ion Device –Preference Quest ionnaire .................................... 35
[IP_ADDRESS]. Four Item s from the Medi cation Delivery  Device 
Assessment ..................................................................................................... 35
[IP_ADDRESS]. Clinical Informat ion Form .............................................................................. 36
9.2. Adverse Events ............................................................................................................ 36
9.2.1. Serious Adverse Events ........................................................................................ 37
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 38
9.2.2. Adverse Event Monitoring with a Systemat ic Questionnaire ................................ 38
9.2.3. Com plaint Handling ............................................................................................. 38
9.3. Treatment of Overdose .................................................................................................38
9.4. Safety........................................................................................................................... 38
H9X-MC-B021(b) Clini calProtocol Page 4
LY21892659.4.1. Electrocardiograms .............................................................................................. 38
9.4.2. Vital Signs ........................................................................................................... 38
9.4.3. Laboratory  Tests .................................................................................................. 39
9.4.4. Safety Moni toring ................................................................................................ 39
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. [ADDRESS_999523] ical Considerat ions................................ ........................................ 40
10.3.2. Treatment Group Comparabilit y........................................................................... 41
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 41
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 41
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 41
[IP_ADDRESS]. Treatment Compliance .................................................................................... 41
10.3.3. Statistical Analyses .............................................................................................. 41
[IP_ADDRESS]. Primary Analyses ........................................................................................... 41
[IP_ADDRESS]. Gated Secondary  Analyses ............................................................................. 41
[IP_ADDRESS]. Exploratory  Analyses ..................................................................................... 42
[IP_ADDRESS].1. Exploratory  1.  DID -PQ Analyses of Items 1 to 8 and 
10............................................................................................................. 42
[IP_ADDRESS].2. Exploratory  2.  Time -to-Train Analyses .................................................... 42
[IP_ADDRESS].3. Exploratory  3.  Suppl emental  Quest ion Analyses ...................................... 42
[IP_ADDRESS].4. Exploratory  4.  Eval uation of  the DID -PQ................................................. 42
[IP_ADDRESS]. Missing Data .................................................................................................. 43
10.3.4. Safety Analyses .................................................................................................... 43
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 43
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 43
10.3.7. Other Analyses ..................................................................................................... 43
[IP_ADDRESS]. Health Economics ........................................................................................... 43
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 43
H9X-MC-B021(b) Clini calProtocol Page 5
LY218926510.3.7.3. Pi[INVESTIGATOR_731696] ....................................................................................... 44
10.3.8. Interim Analyses .................................................................................................. 44
11. References ........................................................................................................................ 45
12. Appendices ....................................................................................................................... 48
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999524] ives/Endpo ints/Stati stical Analyses ...................................................... [ADDRESS_999525] ives and Endpo ints............................................................................... 20
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999526] of Figures
Figure Page
Figure 3.1. Dulaglut ide pen external view. ....................................................................... 16
Figure 3.2. Semaglut ide single -patient -use pen exter nal view. ......................................... 17
Figure 5.1. Study  diagram  for the pati ent preference study ............................................... 21
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999527] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 49
Appendix 2. Study  Governance Considerat ions.................................................................. 51
Appendix 3. Recrui tment Advertisements .......................................................................... 55
Appendix 4. Pi[INVESTIGATOR_731697] .......................................................................... 56
Appendix 5. Pi[INVESTIGATOR_731698] n/Exclusio n Cri teria........................................................ 64
Appendix 6. Confirmation Letter/E -mail............................................................................ 66
Appendix 7. Reminder Phone Call/E -mail ......................................................................... 67
Appendix 8. Main Phase Screening Script .......................................................................... 68
Appendix 9. Main Phase Inclusio n/Exclusio n Cri teria........................................................ [ADDRESS_999528] ion S1 ............................................................................. 74
Appendix 12. Interview and Device Training Guide ............................................................ 75
Appendix 13. Time -to-Train (TTT) Observer Recording Sheet ............................................ [ADDRESS_999529] ions..................................................................... 92
Appendix 17. Global Preference Item .................................................................................. 94
Appendix 18. DID-PQ......................................................................................................... 95
Appendix 19. Four Item s Fro m MDDAB –Ozempic Device ............................................... 96
Appendix 20. Four Item s Fro m MDDAB –Trulici ty Device ................................................ [ADDRESS_999530] ions S2 and S3 .............................................................. 100
Appendix 22. Clinical Informat ion Form ........................................................................... 101
Appendix 23. Protocol  Amendment H9X -MC-B021(b) Summary Crossover Study 
Com paring the Dul aglut ide (Trulicit y) Pen and the Semaglut ide 
(Ozem pic) Pen ............................................................................................. 106
H9X-MC-B021(b) Clini calProtocol Page 9
LY21892651.Synopsis
Title of Study:   
Protocol  H9X -MC-B021:  Crossover Study  Com paring the Dul aglut ide (Trulicit y) Pen and the 
Semaglut ide (Ozempic) Pen
Rationale: 
Positive percept ions of inject ion devices could lead to better treatment adherence, which has 
been shown to have an impact on treatment outcomes in patients with t ype 2 diabetes mellitus
(T2D M) (Khunti et al. 2017 , 2018).   Therefore, it may be useful for clinicians to consider not 
only the efficacy , safety, and cardio vascular effects of glucagon -like peptide -1 (GLP -
1)receptor 
agonists (RA) but also patient preferences of injectio n devices when select ing the most 
appropriate treatment for patients with T2DM
.  The primary purpose of this study  is to determine 
patient preference sbetween the inject ion devices used for the GLP -1 RAs dulagl utide versus 
semaglutide.  The dulaglut ide single -dose pen is a single -dose autoinjector pen that does not 
requi re handling of the needle, which is hidden and automatically  retracts after use (Eli Lilly  IFU 
2017)
.  The semaglut ide single -patient -use pen can be used more than once and does require 
handling of the needle (Novo Nordisk IFU 2017) .  
This study  will also evaluate the time -to-train (TTT) on using both the dulaglut ide and 
semaglutide devices.  One recent study  conducted in Japa n found that the dul aglut ide pen was 
associ ated wi th a significant ly shorter m ean TTT compared to the insulin degludec 
single
-patient-use pen (7.4 minutes v ersus 19.7 minutes; p<.001) (Asakura et al. 2018).   The 
FlexTouch pen used for the insulin degludec (Asakura et al. 2018) is funct ionally  similar to the 
one being evaluated in this study  with semaglut ide.  These results suggest that it is less 
burdenso me for healt h care providers to train pat ients to correctly use the dulaglut ide device
compared to other devices and easier for patients to learn self -inject ion with this device .  The 
study  will examine whether differences in patient preferences and TTT f ollow the same pattern 
in this co mpar ison crossover trial between the dulaglut ide and semaglutide devices in aUS 
sample.   
Summary of Study Design:   
Study  H9X -MC-B021 is an open -label, multicenter, randomized, crossover study assessing 
patient preference (and training time) with the dulaglut ide single -dose pen versus the 
semaglutide single- patient-use pen .  Study  H9X -MC-B021 consists of a single study  visit for 
approximately  [ADDRESS_999531] ion naïve p atients will be recrui ted 
from approximately 14 clinical sites in the US.  The TTT assessment will be conducted in a 
subset of 75 to 80 patients from approximately 5 of the selected US clinical sites.   All 
participants will receive training and perform mock injections on a practice p ad using both 
devices.  However, the order in which the participants are exposed to the devices will be 
rando mized.  Fift y percent (50%) of patients will be randomized to use the dulaglut ide device 
first, while the other half will use the semaglutide devic e first.   Parti cipants will be under the 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999532] ion devices.   Parti cipants will 
also complete a seri es of questionnaires to determine their device preference.  
Prior to commencing the study , a pi[INVESTIGATOR_731699]  10to 20
patients with T2DM.  The purpose of the pi[INVESTIGATOR_731700] a cl ear and streamline dtraining 
procedure for each device in order to finalize the steps of the training approach to use in the main
phase of the study .  The pi[INVESTIGATOR_731701]  290 pati ents with T2DM for the analyses .  
Treatment Arms and Duration:
Patients will  be randomized into [ADDRESS_999533] igation in this study in a 1-time interview .  
Number of Patients:
Parti cipating patients will be randomized to ensure that there are approximately  [ADDRESS_999534] ion naïve part icipants.  
Statistical Analyse s:  Refer to the third co lumn below in Table 1.1.  
Table 1
.1. Objective s/Endpoints/Statistical Analyses
Objectives Endpoints Statistical Analyse s
Primary:
Determine patient 
preference between the 2 
injection devicesThe Global Preference 
Item:  “Overall, which 
device do you prefer?”The Prescott test will be run to examine whether there 
is a statistically significant difference in preference 
between the devices, while controlling for order 
effects (significance level at p<.05).
Gated Secondary:
Compare devices with 
regard to ease of use (To 
be tested if a significant 
difference is found in the 
primary  objective.)Item 9 of the Diabetes 
Injection Device –
Preference Questionnaire 
(DID -PQ)If the primary objective is statistically significant , 
responses to the 5 -point response scale of DID -PQ 
Item 9 (ease of use) will be collapsed into 3 
categories.  The “strongly prefer” and “prefer” 
response options will be combined for each device, 
resulting in 3 categories :  prefer dulaglutide, prefer 
semaglutide, and no preference.  The Prescott test will 
be run to examine whether there is a statistically 
significant difference in preference for ease of use 
between the devices, while controlling for order 
effects (significance level at p<.05).
Exploratory 1:
Collect data to support the 
preference question in the 
primary  objectiveResults from the DID -
PQ Items 1 to 8 and 10Explo ratory  analy ses of Items 1 to 8 and 10 of the 
DID-PQ will follow the same procedures as those for 
the gated secondary objective described above. 
H9X-MC-B021(b) Clini calProtocol Page 11
LY2189265Objectives Endpoints Statistical Analyse s
Exploratory 2:
Compare t ime-to-train
(TTT) on the dulaglutide 
and semaglutide devicesResults from the 
Observer Recording 
SheetCarryover effects will be examined.  If there are no 
significant carryover effects, then TTT for both the 
first and second trainings will be used in this analysis.  
If there is a significant carryover effect, then this 
analy sis will use data for whichever device is trained 
first. The average duration required to train and 
successfully inject each device will be assessed using 
the linear model appropriate for a crossover design.  
Exploratory 3:
Examine patients’ 
willingness to use each of 
the devices after being 
trained on bothResu lts from the 3 
Supplemental QuestionsUsing the data from the 3 Supplemental Questions, 
descriptive analyses will be run to examine 
willingness to use each of the devices after being 
trained on both.
Exploratory 4:
Validation of the DID -PQ Questionnaire validation 
analy ses (i .e., known -
groups and construct 
validity)The primary validation approach will be to examine 
known -groups validity by [CONTACT_731758] -PQ 
responses of patients categorized based on the 
responses to the Global Preference Item. 
Construct validity will be assessed by [CONTACT_731759]-PQ responses to responses on 4 items selected 
from the Medication Delivery Device Assessment 
Battery  (Yu et al. 2017).  Cross -tabulatio n tables of 
these 4 items by [CONTACT_731760]-PQ items will be presented. 
In addition, the DID -PQ exploratory approach for 
comparing devices will be examined relative to the 
ancillary  measures.
H9X-MC-B021(b) Clini calProtocol Page 12
LY21892652.Schedule of A ctivities
Table 2.1. Schedule of A ctivities
ProcedurePi[INVESTIGATOR_42751] :  Conducted at 1 US 
Location1
Approximately n ≈10to 20Main Phase :  Conducted at 
Approximately 14 Clinical Sites 
across US2
Approximately n ≈ [ADDRESS_999535] study screening; if eligible, schedule visit X X
Main Phase :  Inclusion/Exclusion Form X
Pi[INVESTIGATOR_42751] :  Inclusion/Exclusion Form X
Completion of written informed consent X X
Randomization X X
Participant completes Supplemental Question S1 X X
Participant completes training and performs mock injections with 
randomized Device 1 X X
If TTT, the assigned study team observer completes Observer 
Recording Sheet for Device 13 X X
INTERVIEW BREAK 1:  Participant will be offered a restroom and 
water breakX X
Participant completes Demographic Form X X
Participant completes training and performs mock injections with 
randomized Device 2 X X
If TTT, the assigned study team observer completes Observer 
Recording Sheet for Device 23 X X
Study team interviewer administers pi[INVESTIGATOR_731702] X
Study team interviewer completes Interviewer Recording Sheet X X
OPTIONAL INTERVIEW BREAK 2 X
H9X-MC-B021(b) Clini calProtocol Page 13
LY2189265ProcedurePi[INVESTIGATOR_42751] :  Conducted at 1 US 
Location1
Approximately n ≈10to 20Main Phase :  Conducted at 
Approximately 14 Clinical Sites 
across US2
Approximately n ≈ 290
Screening Study Visit Screening Study Visit
Participant completes Global Preference Item X X
Participant completes DID -PQ X X
Participant completes 4 i tems selected from the MDDAB about each of 
the devices under investigationX X
Participant completes Supplemental Questions S2 and S3 X X
Clinical site completes Clinical Information Form X
Abbreviations :  DID-PQ = Diabetes Injection Device –Preference Questio nnaire ; TTT = time-to- train; MDDAB = Medication Delivery Device Assessment Battery .
1Pi[INVESTIGATOR_42751]:   Recruiting, screening/scheduling, and the in -person interviews will be conducted by [CONTACT_731761].
2Main Phase:  R ecruiting and screening/scheduling will be done by [CONTACT_977] s. The in -person interviews will be conducted by [CONTACT_731761].
3TTT interviews:  All pi[INVESTIGATOR_731703].  However, for the main phase, the TTT assessment will only be conducted in a subs et of the main 
phase participants with approximately 75 to 80 pati ents across an estimated 5 clinical sites.
H9X-MC-B021(b) Clini calProtocol Page 14
LY21892653.Introduction
3.1. Study Rationale
Glucagon -like peptide -1 (GLP -1) receptor agonists (RAs) are often recommended as part of 
combinat ion therapy  for type 2 di abetes mellitus ( T2DM)when oral medication alo ne does not 
provi de sufficient glycemic control (Inzucchi et al. 2012; NICE 2014) .  These injectable 
treatm ents have been shown to be effect ive in lowering glycated hemoglo bin A1c (HbA1c ) with 
a low ri sk of hypoglycemia and a potential benefit of weight loss (Aroda et al. 2012; Trujillo et 
al. 2015; Htike et al . 2017) .
Dulaglut ide is a GLP -1 RAthat was approved by  [CONTACT_731762] 2014 (Edwards and 
Minze 2015) .  The safet y and efficacy for HbA1c control were demonstrated in several  clinical 
trials invo lving over 5000 patients ( Dungan et al. 2014; Nauck et al. 2014; Umpi[INVESTIGATOR_124012] e t al. 
2014; Wysham et al. 2014; Blonde et al . 2015; Giorgino et al. 2015; Dungan et al. 2016; Ludvik 
et al. 2018; Pozzilli et al. 2017 ; Tuttl e et al . 2018 ).  The dul agluti de device i s a single -dose 
autoinjector pen that does not require handling of the needle, which is hidden and automat ically 
retracts after use ( Eli Lilly IFU 2017 ).  The dulaglutide device is notably different from devices 
used wi th the other m edications in this class.  In this study, the dulaglutide device will be 
compared to the sem aglut ide device, which is a newer weekly GLP -1 RA, administered via a 
single- patient-use pen .  The semagl utide device can be used more than once and does require 
handli ngof the needle (Novo Nordisk IFU 2017) .  
Positive percept ions of inject ion devices could lead to better treatment adherence, which has 
been shown to have an impact on treatment outcomes in patients with T2DM (Khunt i et al. 2017, 
2018) . Therefore, it may be useful for clinicians to consider not only the efficacy, safet y, and 
cardi ovascular effects of GLP -
[ADDRESS_999536] ion devices used for the GLP -1 RAs 
dulaglut ide versus semaglut ide.  T his study will also evaluate the time -to-train (TTT) on using 
both the dulaglut ide and semaglutide devices.   One recent study  conducted in Japan found that 
the dulaglutide device was associat ed with a significant ly shorter mean TTT than the 
single- patient use-penused for insulin degludec (7.4 minutes v ersus 19.7 minutes; p<.001) 
(Asakura et al. 2018).  The FlexTouch pen used for the insulin degludec (Asakura et al. 2018 ) is 
funct ionally  simil ar to the one being evaluated in this study  with semaglutide.  These findings 
and other results suggest that it may be less burdensome for health care providers (HCPs) to train 
patients to correctly use the dulaglut ide device compared to other devices and easier for patients 
to learn self -inject ion with this device.  The study  will examine whether differences in patient 
preferences and TTT follow the same pattern in this comparison crossover trial between the 
dulaglut ide and semaglutide devices in a US samp leof patients with T2DM .  All pat ientswith 
T2DM included in the study  must be self -inject ion naïve to all injectable treatment, in efforts to 
minimize potential bias based on any  previ ous experi ence.  GLP -[ADDRESS_999537] ion naïve part icipants.  
H9X-MC-B021(b) Clini calProtocol Page 15
LY2189265Please note: The protocol language will use the generic names of the medication in the 
devices (i.e., semaglutide and dulaglutide). However, to provide a naturalistic experience that 
most closely mirrors real-world treatment process, the study participants will be trained to use 
the branded injection devices that are used by [CONTACT_731763]. These pens feature the brand names (i.e., Ozempic and Trulicity) more 
prominently than the generic names. Therefore, to minimize confusion and ensure that study 
materials are clear for the respondents, the patient- completed questionnaires will use the 
brand names that are clearly presented on each pen. These names will always be presented in 
alphabetical order (i.e., Ozempic followed by [CONTACT_731764]). Importantly, the use of the branded 
devices is not intended to be promotional in nature.
Appendix [ADDRESS_999538] other medicat ions in the GLP -1RAclass.  For example, 2 discrete 
choice experiments ( 1 in the [LOCATION_006] and the other in Japan) found that patients preferred the type o f 
delivery  system  used for dulaglutide over the delivery  system  used for li raglut ide 
(Gelhorn etal.2015, 2016) .  Similarly, healt h state utilit y studi es conducted in the [LOCATION_006] and Italy  
found that pati ents preferred the dulaglut ide pen attributes over the attributes of devices used 
with com parator treatm ents (Matza et al . 2017a; Matza et al . 
2018b).
Research on perceptions of these injection devices has also been conducted among patients who 
have personal experience wit h the devices.  For example, a recent naturalist ic study  conducted in 
over 400 patients with T2DMinthe US found that the dulaglut ide pen was associated with 
percepti ons of  greater ease -of-use and convenience than the liraglut ide device (Matza et al. 
2018a).  Furthermore, the subset of [ADDRESS_999539] ion Device –Preference Questionnaire (DID -PQ), whi ch was designed to assess 
preferences between non- insulin inject ion devices .  The dul aglut ide device was also preferred 
over the single- patient-use pen device (used with insulin degludec) in a recent crossover study  
conducted among self -inject ion naïve patients with T2DMin Japan (Asakura et al. 2018) .  In 
addition, the dul aglut ide pen was associated with greater ease -of-use and l ess time required for 
training.  The dulaglut ide device was also found to be a safe and effect ive device for use by 
[CONTACT_731765]-naïve patients with T2DMin a 4-week Phase 3b usabilit ytrial (Matfin et al. 2015) .
3.2.1. Dulaglutide Pen
The dul aglut ide single -dose pen ( Figure 3.1) i s a single -use autoinjector desi gned for a 
once -weekly subcutaneous (SC) inject ion of dulaglutide in eit her a 0.75 mg or 1.5 mg dose for 
adult pati ents wi th T2DM
(Eli Lilly IFU 2017) .  Dul aglut ide may be self -administered or 
administered by  [CONTACT_1962]’caregivers or HCPs .
The dul aglut ide pen is designed to deliver a SC injection wit hout the need for management of the 
inject ion site such as needle insert ion into a skin fold.  The needle in the dulagl utide pen is29
H9X-MC-B021(b) Clini calProtocol Page 16
LY2189265gauge .  The dul aglut ide pen is approximately 16 cm in length and is constructed of polymer 
molded components, metal springs, and the pen label .
Figure 3.1. Dulaglutide pen external view.
The pen is prepared for use by [CONTACT_731766] (which also removes a rigid needle shield 
from the syringe), pl acing it at the inject ion site, and rotating the lock ring to unlock.  The pen is 
then used by  [CONTACT_731767] (green button in Figure 3.1).  This action releases a 
spring -enabled plunger rod that inserts the needle to a predetermined depth and then delivers the 
contents of the sy ringe into SC tissue.  The plunger rod init iates a second spring -enabled 
mechanism to automatically  retract the needle after the dose i s completelydelivered .  The 
retracted sy ringe and needle is permanently contained wit hin the structure of the pen after the 
inject ion cycle is complete.   The ent ire pen i s disposed af ter each use.
3.2.2. Semaglutide Pen
Ozem pic is a registered trademark of Novo Nordisk A/S. All other trademarks are the property  of 
their respect ive owners.
The semaglut ide single -patient-use pen ( Figure 3.2) i s a mul ti-use, disposable inject ion device 
designed for once -weekly SC injection o f semagluti de
(Novo Nordisk IFU 2017) .  Adult patients 
with T2DM are prescribed semaglut ide in an escalatin g dose regimen of 0.25 m g starting dose 
for 4 weeks, fo llowed by 0.5 m g, and a possible dose escalat ion after 4 weeks to 1.0 mg. The 
0.25 m g and 0.5 m g dose sare administered by 1 pen, wi th patients requiring 1.0 mg switching to 
the respective 1.0 mg pen device.  Sem agluti demay be self -administered or administered by  
[CONTACT_1962]’ caregivers or HCPs .
The semaglut ide pen is designed to deliver a SC inject ionin a manner similar to a ninsulin pen.  
The exposed needle length is variable, using NovoFine®needles ranging from [ADDRESS_999540] a 32 gauge . 

H9X-MC-B021(b) Clini calProtocol Page 17
LY2189265Figure 3.2. Semaglutide single -patient - use pen external view.
According to the instructions for use (IFU), the semaglut ide pen is prepared by [CONTACT_133552] a new 
needle via a push -on retenti on m echanism , priming the pen by  [CONTACT_731768] l and 
depressing the dose knob, turning the dose selection knob to the appropriate dose, insert ing the 
needle under the skin ,and pushing the dose knob to the end of travel. The patient i s then 
instructed to count to 6, rem ove the needle fro m the skin, and safely discard the used needle.
3.3. Benefit/Risk Assessment
While there are no di rect therapeuti c benefit sto pati ents parti cipating in the study , the resul ts 
from this study  will offer valuable insights into the patient preference and TTT of different 
inject ion devices in the same drug class.  Injection inertia is a docum ented and valid concern in 
the T2DM treatment paradigm ,and t his study  will provi de a further understanding of T2DM 
patients’ preferences for inject ion devices themselves (Khunt i et al. 2013 , 2016
; 
Norrbacka etal.2018) .  The risk o f this study  will be minimized because the mockinject ions 
will be performed in pract ice pads and parti cipants will be under the direct supervisio n of a study  
interviewer when handling the inject ion devices .  Parti cipants are not inj ecting themselves in this 
study .
3.4. Risks and Foreseeable Adverse Events/Device Effects
The fo llowing i s a list of potential risks associated with participat ion in this clinical study :
Accidental  needlest ick injury
Accidental exposure to drug product (acci dental  self-inject ion)
The fo llowing i s a list of potential risks associated with the study  devices:
Improper funct ioning and/or mechanical failure of the device or its components ( for 
example ,no inject ion, slow inject ion intopractice pad, parti al injecti on into practice pad, 
cracked sy ringes, hi gh force to operate devi ce, damaged needle)
Skin reaction ( for example, after acci dental  needlesti ck)
Nausea, gastrointestinal event, or low blood sugar potentially associated with exposure to 
drug product
3.5. Methods to Minimize Risks
Training on both study  devices will be provided by [CONTACT_731769] (Eli Lilly IFU 2017; Novo Nordisk IFU 2017).  Training for correct sharps 
handling/disposal is part of the study  training, and no cross contaminat ion is expected due to 
each parti cipant receiving their own device, as well as injecting drug into a practice pad instead 

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999541] if necess ary.  These clinical staff members will follow 
(monitor) the pati ent as per clinical judgment for a potential adverse event (AE) and fo llow the 
appropriate device -reporti ng procedures.  With patients recruited from the other four sites, the 
interviews will be conducted at interview facilit ies where medical pro fessio nals (e.g., nurses) 
hired specifically  for thi s study  will be ready  to assist if necessary in case of AEs such as 
unant icipated needlesticks or self -inject ion.  
It is very  unlikely that a parti cipant will receive an accidental dose of medication for several 
reasons:  
1.The parti cipants will only handle the devices under direct supervisio n of a study  
interviewer after the interviewer has demonstrated how to use the device on a mock 
inject ion pad.
2.Patients will  be told that they  should not inject themselves, and these devices will only be 
used for m ock injecti ons into an inject ion pad.
3.If a participant appears to begin inject ing themselves rather than the inject ion pad, the 
interviewer woul d immedi ately interrupt the process and stop the participant from 
completing this self -inject ion. 
4.In the unlikely  circumstance that a patient does have an accidental “needle st ick,” no 
medicat ion woul d be injected unless the pat ient cont inues wit h the inject ion procedure.  It 
is not possible for a patient to accidentally deliver a full dose of medicat ion without 
intending to do so because a series o f steps needs to be fo llowed to inject a medicat ion 
dose.  These steps for dulaglut ide and semaglut ide are described below:
a.Dulaglut ide: The participant would need to place the device over their skin, 
unlock the device by [CONTACT_282979] a lock ring, press the inject ion button, and ho ld the 
device in place for approximately 5 –10 seconds.  
b.Semaglut ide: The participant would ne ed to turn the dose selector to a dose, insert 
the needle into their skin, press the inject ion button, and wait approximately [ADDRESS_999542].  These two 
medicat ions are GLP -1 receptor agonists, not insulin.  The refore, the ri sk of hypoglycemia after 
H9X-MC-B021(b) Clini calProtocol Page 19
LY2189265a single dose is low, and steady  state therapeuti c medi cation concentration is not achieved for 
approximately  25 days wi th dulaglut ide and 4 –[ADDRESS_999543] udy will be aware of this risk and ready  to give oral  sugar 
preparati ons.  Medi cal personnel woul d also be informed of the potential for transient GI side 
effects of a single dose which would be easily manageable with antiemet ics.  
More detailed informat ion about the known and expected benefits and risks of dulagl utide and 
semaglutide may be found in the fo llowing:  Protocol Sections 3.3and 3.4.
H9X-MC-B021(b) Clini calProtocol Page 20
LY21892654.Objectives and Endpoints
Table 4.1shows the objectives and endpo ints of the study .
Table 4
.1. Objectives and Endpoints
Objectives Endpoints
Primary:
Determine patient preference between the 2 
injection devicesThe Global Preference Item :  “Overall, which device do 
you prefer?”
Gated Secondary:
Compare devices with regard to ease of use (t o be 
tested if a significant difference is found in the 
primary  objective.)Item 9 of the Diabetes Injection Device –Preference 
Questionnaire (DID -PQ)
Exploratory 1:
Collect data to support the preference question in 
the primary objectiveResults from the DID -PQ Items 1 to 8 and 10
Exploratory 2:
Compare t ime-to-train on the dulaglutide and 
semaglutide devicesResults from the Observer Recording Sheet
Exploratory 3:
Examine patients’ willingness to use each of the 
devices after being trained on bothResu lts from the 3 Supplemental Questions
Exploratory 4:
Validation of the DID -PQ Questionn aire validation analyses (i.e., known -groups and 
construct validity)
H9X-MC-B021(b) Clini calProtocol Page 21
LY21892655.Study  Design
5.1. Overall Design
Study  H9X- MC-B021 is an open -label, multicenter, randomized, crossover study  assessing 
patient preference (and training time) for the dulaglut ide pen versus the semaglut idepen(Figure 
5.
1).  Approximately [ADDRESS_999544].  Lilly will provide all 

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999545] ions.  The drug name s will be visible to patients and the 
device names will not be blinded to the participants.  The devices are physically  different from 
one another , thus even if the participants were blinded to the pens they coul d discern the name [CONTACT_731797].  Mo re details about blinding are provided in Secti on 7.3.
5.2. Number of Participants
It is expected that a pproximately double the estimated total sample will  be screened (i .e., an 
estimated 580 participants across all clinical sites, 48 to 50 participants per site will be screened ) 
to achieve [ADDRESS_999546] scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient .
5.4. Scientific Rationale for Study Design
The mu
lticenter crossover study  design was selected to control for order effects while allowing 
patients to di rectly co mpare [ADDRESS_999547] (ERB) approval will be obtained before study  implementation.  
More details about the regulatory and ethical considerati ons for this study , including the 
inform ed consent process ,are provided in Appendix [ADDRESS_999548] ion efforts willbe conducted by  [CONTACT_731761] (a business unit within Pharmaceutical Product 
Development, LLC [[COMPANY_003]]).  For the main phase, approximately  14clinical si tes across the US 
will be ident ified.  These clinical sites will recrui t, confi rm patient eligibilit y, and schedule all 
study  interviews.   
The int erviews that do not include the TTT assessment will take place at the 
actual clinical sites .  Approximately [ADDRESS_999549] the study  interviews in -person.   
Any study  interviews conducted at non -clinical facilit ies will require a me dical  prof essional (for 
example , nurse or param edic) to be on site in case of AEs such as unant icipated needlesticks.  
H9X-MC-B021(b) Clini calProtocol Page 23
LY21892655.5.1. Pi[INVESTIGATOR_42751] :  Participant Recruitment and Screening 
Procedures
Approximately  10to 20participants will be recruited for the pi[INVESTIGATOR_731704]-approved 
newspaper advertisements , 
internet classified advertisements, and/or other advertisements in 
social media outl ets (Appendix 3 ).  For advertisements, study  staff fro m Evidera will arrange 
toll-free phone numbers for interested participants to call and leave messages.  Study  staff will 
also arrange a study -specific e -mail address that participants can use to respond to 
advert isements and provide their contact [CONTACT_731770] e -mail.  Study  staff will regularly check 
the voicemail box and e -mail inbox to prompt ly respond to interested participants.  The 
voicemail box will be password protected ,and only assigned study  team  members will have 
access to the password to obtain participants’ contact [CONTACT_4203].  For the study  e-mail account, 
only the necessary  study  team  members will  be granted permissio n to the e -mail accou nt by 
[CONTACT_731771].
Type 2 di abetes m ellitusdiagnosi s will  be verified through proof of oral antidiabet ic medicat ion
use.  Study  staff will screen potential participants who respond to the advertisement to ensure 
that they  meet study  inclusion criteria (Appendix 4 ).  In addit ion to the inclusio n/exclusio n 
criteria, several demographic questions such as age, gender, and emplo yment status will be asked 
tomonitor eligibilit y and sample diversit y throughout the recruitment process .  If any 
inclusio n/excl usion criteria cannot be confirmed via phone screening ( for example , parti cipant’s 
cogni tive abilit y to understand the device trainings ), the final eligibilit y determinat ion will be 
established at the time of the interview ( Appendix 5 for Incl usion/Exclusi on Form will be 
completed at th e beginning of the interview).   
Those participants considered eligible based on screening will be scheduled for an interview by 
[CONTACT_49124].  All pil ot phase parti cipants will part icipate in the TTT assessment.  Any ident ifying 
inform ation (for example , names, addresses, tel ephone numbers) that is recorded on the 
screening/scheduling scripts will be kept in a limit ed access, locked filing cabinet .  Prior to the 
interviews, proj ect staff will send participant ’s confi rmation (and direct ions to the interview 
location) by e -mail or mail according to participant’s preference (Appendix 6 ).  Reminder phone 
calls will be made to participant s 1 day before the interview.  During previous studies, it has 
been found that the se reminder phone calls reduce the likelihood that participants will fail to 
attend t heir appoint ment(Appendix 7 ).  However, it might not be possible to speak to all 
participants 1 day before the interviews ( for example ,no answer), if so, e-mail reminders will  be 
sent ( Appendix 7 ).  At least 1 reminder will be sent to all pi[INVESTIGATOR_731705] r 
study  interview when possible from the assi gned study  team  member . 
5.5.2. Main Phase :  Participant Recruitment and Screening 
Procedures
The Evidera clinical site database will be used to ident ify the appropriate US clinical sites for 
inclusio n in the study .  Sites in a vari ety of geographical l ocati ons wi th diverse pat ient 
popul ations will b e recrui ted to ensure sample diversit y.  Approximately [ADDRESS_999550] ion naïve pat ients with T2DM .
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999551] mirror for the second staff member to time the training.  
The non -TTT study  interviews will be conducted at the actual clinical sites the T2DM 
participants are recruited fro m throughout the US.
Clinical site staff will ident ify and verify the init ial eligibilit y of parti cipants through a records 
review.   
Aclinical site staff member will approach the potential participant in person (at the 
clinic or by  [CONTACT_648]) and briefly introduce the study  using a standard screening script ( Appendix 
8).  If the patient is interested, the study  will be expl ained in full deta il, and a full screening will 
be conducted to ensure eligibilit y (Appendix 9 ).  Clinical staff will schedule all study  interviews 
during the specifi
ed timeframe when Evidera staff will be conduct ing the study interviews for 
their site.  Clinical staff will track recruit ment efforts using the participant recruitment tracking 
log (Appendix 10 ).  Any ident ifying information ( for example , names, addresses, tel ephone 
numbers) that is recorded on the screening/scheduling scripts will be kept in a limited access, 
locked filing cabinet .  
Prior to the interviews, clinical site staff will send participants confirmat ion (and directions to the 
interview l ocati on) by e -mail or post according t o parti cipant’s preference ( Appendix 6 ).  
Reminder phone calls will be made to participant s 1 day before the interview.  During previous 
studi es, it has been found that these reminder phone calls reduce the likelihood that participants 
will fail to a ttend their appo intment (Appendix 7 ).  However, it might not be possible to speak to 
all participants 1 day before the interviews ( for example ,no answer), if so, e-mail reminders will  
be sent ( Appendix 7 ).  At l east 1reminder will be sent to all participants about their study  
interview when possible from the clinical sites .
5.5.3. Overview of Study Visit Procedures for the Pi[INVESTIGATOR_731706] 2.1provides an overview of the study schedul e of activities.  During the study  visit,
participants will begin with the co mpletion o f theinformed consent . The order in which self-
inject ion naïve participants are trained on using each device will then be rando mized using a 
validated software sy stem .  More details about the rando mizat ion process are described in 
Secti on 7.2.  Half the participants will be rando mized to be trained and perform mock inject ions 
on the dulaglut ide device first fo llowed by  [CONTACT_731772] o f the 
participants will use the devices in the reverse order.  All participants will co mplete a 
Suppl emental Quest ion (Appendix 11 ) at the beginning of the study  to determine their baseline 
willingness to use a diabetes injectable medicat ionprior to being exposed to either the 
dulaglut ide or semaglut ide devices.
Trained inte rviewers will fo llow the study  Interview and D evice Training Guide ( Appendix 12 ), 
in order to standardize the presentation of devices to participants and ensure that the training is 
clear and not bi ased in favor of either device .  For the pi [INVESTIGATOR_32731], the trained interviewers will 
tryseveral training options for each device to determine the finalized steps of the training 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999552] ions on a practi ce pad after being trained in the use of each device.  
During the interview, if the participant does not complete one of the critical steps or if the steps 
are com pleted out of order, the Interview and Device Training Guide ( Appendix 12 ) provi des 
interviewers instructi ons for handling these situat ions.  The participant will be allowed [ADDRESS_999553] ion(s) for each device.  If after [ADDRESS_999554] the necessary  
training t imes using the TTT Observer Recording Sheet for each device (Appendix 13 ).  In 
between the trainings on each device, all participants will be given a restroom and wate r break.  
During this break ,participants will also complete the Demographic Form ( Appendix 14 ).
Once participants have attem pted each device training and mock inject ion(s)on the practice pad, 
interviewers will co mplete the Inter viewer Recording Sheet to docum ent randomizat ion order 
and if the patient was able to complete both device trainings (Appendix 15 ).  Pi[INVESTIGATOR_731707] a series of interview quest ions about the training 
procedures ( Appendix 16 ).  Based on interviewer experiences and pat ient feedback during these 
estimated [ADDRESS_999555] ions, pi[INVESTIGATOR_731708] .  
Parti cipants will then be asked to complete questionnaires to report their preferences between the 
2 devices.  Specifi cally , parti cipants will com plete a Global Preference Item (Appendix 17 ) and 
the DID -PQ (Appendix 18 ).  Four items selected from the Medicat ion Delivery Device 
Assessment Battery  (MDDAB) (Matfin et al. 2015; Yu et al. 2017) will be asked of participants
about each of the devices under investigation to use in the validat ion of the DID- PQ (Ozem pic 
device- specific questi ons: Appendix 19 ;Trulici ty device -specific questi ons: Appendix 20 ) .  
These addit ional quest ions will be co mpleted in the order the participants were randomized to 
use the devices.   Parti cipants will al so com plete Supplemental Quest ions S2 and S3 to determine 
their end of study  willingness to use each of the study  injecti on devices (Appendix 21 ).  
Pi[INVESTIGATOR_731709]  90to 120minutes including consent ing and 
training in device procedures.   All pi[INVESTIGATOR_731710] m ain phase participants (i.e., a specified amount between $100 and $[ADDRESS_999556]) because they  will be participat ing in debriefing procedures and 
possibly  multiple training approaches .  The pi[INVESTIGATOR_731711].
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999557] fo llowed by  [CONTACT_731773].  
All participants will complete a Supplemental Question ( Appendi x 11) at the very  beginning of 
the study  to determine their baseline willingnes s to use a diabetes injectable medicat ion prior to 
being exposed to either the dulaglut ide or semaglutide devic es.  
Trained study  interviewers will fo llow the study  Intervi ew and Device Training Guide 
(Appendix 12 ) to standardi ze the presentati on of  devices to parti cipants and ensure that the 
training is clear and not biased in favor of either device.  Based on findings from the pi[INVESTIGATOR_32731], 
the finali zed main phase training appr oach will be conducted with the patients for each device
including a detailed demo nstrati on by [CONTACT_20679].  The same standardized interview 
approach will be used for all the main phase patients.  For each device, patients w ill be given the 
IFU and asked to read it.  Then the interviewer will demonstrate how to use the device.  
Parti cipants will perform  mock inject ions on a practice pad after being trained in the use of each 
device
.  Pati ents will  have access to the IFU durin g the ent ire training and inject ion process.  If 
the participant does not complete one of the crit ical steps or if the steps are completed out of 
order, the Interview and Device Training Guide ( Appendix 12 ) provi des interviewers instructions 
for handling these situat ions.  The participant will be allowed [ADDRESS_999558] ion(s) for each device.  If after [ADDRESS_999559] the partic ipant to stop using the device and proceed ahead with the 
interview.  
For those participants selected for the TTT assessment (i.e., a subset of approximately 75to [ADDRESS_999560] imated 5 clinical sites) , the assessments will be done in an off -site facility to 
allow for the discreet timing o f the training event ( for example , 1-way mirror).  The appropriate 
staff member will discreet ly record the necessary training times using the TTT Observer 
Recording Sheet for each device (Appendix 13 )
.  In between the trainings on each device, all 
participants will co mplete the Demographic Form ( Appendix 14 ).  
Once part icipants have attempted each device training and mock inject ion(s) on the practice pad, 
interviewers will co mplete the Interviewer Recording Sheet to document randomizat ion order
andif the patient was able to com plete both device trainings ( Appendix 15 ).  Parti cipants will 
then be asked to complete questionnaires to report their preferences between the 2 devices.  
Specifically , partici pants will com plete a Gl obal Preference Item ( Appendix 17 ) and the DID -PQ 
(Appendix 18 ).  Four items selected fro m the MDDAB (Matfin et al. 2015; Yu et al. 2017) will 
be asked of participants about each of the devices under invest igation to use in the validation o f 
the DID -PQ (Ozempic device -specific quest ions:Appendix 19 ; Trulicit y device -specific 
questi ons: Appendix 20 ).  These addit ional quest ions w ill be co mpleted in the order the 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999561] ion devices (Appendix 21 ).  A Clinical Informat ion Form  (Appendix 22 ) will also be 
completed by  [CONTACT_731774] .  
Main phase inter view will last approximately  60to 90 minutes including consent ing and training 
in device procedures.   The maximum time for all study  procedures is 90 minutes as specified in 
the consent for m.  All main phase parti cipants will be rem unerated a specified amount between 
$100 and $150 (via Greenphire ClinCard) for thei r time and travel  time to the study  interview.  
5.6. Justification for Dose
The devices used for this study will be commercialized inject ion pens containing non -modified 
commercial product with stickers on the devices indicat ing for use in clinical trial .  However, no 
active drug will be administered because patients will  not be inject ing themselves.  Instead, 
patients will  perform mock inject ions into a practice pad after being trained in the use of each 
device by [CONTACT_731775] . Specifically, the patients will be trained on devices that contain 
the lowest dose (i.e., dulaglut ide = 0.75mg; semaglutide = 0.25mg) for both treatm ents for saf ety 
concerns ( for example , acci dental  needle st ick) and because these are the typi[INVESTIGATOR_731712] 2 products in the US .  However, it is crit ical to acknowledge that the 
devices are very similar across all drug strengths.   Therefore, the study  findings could be 
applicable to other dul aglutide and semaglut ide device doses , as well as other antidiabet ic drugs 
using the same devices .  
H9X-MC-B021(b) Clini calProtocol Page 28
LY21892656.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  if they meet all the following criteria at 
screening :
Participant Characteristics
[1] are at l east aged ≥18 years at the time of screening
[2] diagnosed with ty pe 2 di abetes
[3] self-inject ion naïve to all injectable treatment ( for example , diabetes 
therapi [INVESTIGATOR_731713] m edical condit ions)
[4] i nject ion naïve to performing all injectable treatment ( for example , diabetes 
therapi [INVESTIGATOR_731713] m edical condi tions) to others
[
5] m ust currently receive oral treatm ent for thei r type 2 di abetes
[
5a]pi[INVESTIGATOR_731714]: must be able to bring proof of their 
oral treatment prescription for type 2 diabetes to the interview (for 
example , the m edicat ion itself, the m edicat ion packaging, a prescript ion 
note, or a letter from their doctor ).  This criterion does not apply to the 
main phase because main phase participants will have diagnoses 
confirmed by [CONTACT_731776]’ diabetes 
and treatment .
[
6] w illing and able to attend an in - person interview sessio n
[7] a ble to read, speak, write, and understand the English language
[
8] able and willing to give signed informed consent prior to study  entry  
[9] able to complete the protocol requirements
6.2. Exclusion Criteria
Parti cipants will be excluded fro m study  enrollment if they meet any  of the f ollowing criteria at 
screening:
Medical Conditions
[
1] c urrently diagnosed with gestational diabetes and/or ty pe 1 di abetes
[
2] c ognitive or phy sical difficult ies that could interfere with abilit y to 
understand the training , perform  the inject ion tasks, or complete the study  
questionnaires as judged by [CONTACT_093]
H9X-MC-B021(b) Clini calProtocol Page 29
LY2189265Prior/Concurrent Clinical Trial Experience
[3] are currently  enrolled in any other clinical study  involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically 
or medically com patible with this study
[
4] h ave participated, within the last [ADDRESS_999562].  
Other Exclusions
[
5] i s a heal th care practi tioner who is trained in giv inginjections
[6] for m ain phase participants only:   Invest igator , site personnel ,or 
immediate famil y member of invest igator or site personnel .  Immediate 
family is defined as a spouse, parent, child, or sibling, whether bio logical  or 
legally adopted
[7] i s an emplo yee of any o f the following co mpanies:  Eli Lilly and Com pany , 
Novo Nordisk , Evi dera,or [COMPANY_003]
[8] currently pregnant
6.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999563] igator or his/her designee is responsible for the fo llowing:
Explaining the correct use of the invest igational agent(s) to the patient
Verifying that instructions are fo llowed properly
Main taining accurate records of invest igational product dispensing and co llection
At the end of the study ,returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769]
7.1.1. Packaging and Labeling
The dul aglut ide and semaglut ide d evices will be labeled according to applic able regulatory  
requi rements. The devices used in the study shall be securely stored until returned or destroy ed 
according to instructions fro m the sponsor. Information such as lot number, quant ity, and 
disposi tion of  device(s) used during the clinical study  shall  be docum ented.
Refer to the device labeling/instructions for use (IFU) for the fo llowing:
Instructi ons regarding storage and handling requirements, preparation for use, 
pre-use checks, and any precaut ions to be taken after use or disposal.
Summary  of necessary  training and experience required.
Descript ion of procedures for use.
7.1.2. Medical Devices 
The m anufactured medical devices provided for use in the study  are the dulaglutide pen and the 
semaglutide pen.  
7.2. Method of Device Assignment
For the pi[INVESTIGATOR_32731], assignment to device order study  groups will be randomized using a 
validated software sy stem .
For the main phase, a ssignment to device order studygroupswill be determined by a 
computer -generated random sequence using an interac tive web -response system (IWRS).  The 
IWRS will be used to assign the first devi ce to be used by [CONTACT_102] .  Randomizat ion will occur 
at the study  level in efforts to make sure that there area comparable number of patients who start 
with the dulaglut idedevice versus the semaglutide device across the ent ire study  popul ation.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999564] dose per device (i.e., dulaglut ide = 0.75mg; semaglut ide = 0.25mg).  
7.3. Blinding
This is an open -label study .  All participants will be trained and perform mock inject ions on a 
practi ce pad using l abeled dul aglut ide and semaglu tide devices with the brand names of Trulicit y 
and Ozempic on the pens as displayed in Figure 3.1andFigure 3.2, respectively .  
7.4. Dosage Modification
Although dose modificat ion is not an objective of this study, informat ion on how to modify  a 
dose will be provided in the training for each device as this informat ion is typi[INVESTIGATOR_731715] ( Appendix 12 ).  
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his/her designee is res ponsible for the following:
Obtaining the correct number of devices in advance of each interview.  Staff 
performing all the trainings must have received all the necessary training for both 
devices.  
Storing the study  devices in a secure and monitored area in accordance wit h the 
labeled storage condit ions with access limited to th e invest igator and authorized 
study  staff.
Obtaining the appropriate number of practi ce pads to perform all the mock 
inject ions and fo llowing the req uired instructions to dispose of all the materials 
used in the device trainings and mock inject ions.
7.6. Treatment Compliance
Patient com pliance wi th study  procedures will be assessed at each visit.  Patients will be properly 
trained on how to us e and perform mock inject ions with both the dulagl
utide and semaglutide 
devices.  The patients will be allowed several attempts to fo llow the instructi ons and perform the 
mock injecti ons.  It will be the disc retion of  the study  interviewer to determine if the pat ient is
not capable of co mpleting the study i nterview, including the mock injections and /or
questionnaires , and shoul d be terminated.  More details about study  discont inuation are provi ded 
in Secti on 8.
7.7. Concomitant Therapy
All conco mitant therapi [INVESTIGATOR_731716] -injected (per the exclusio n criteria) .
7.8. Treatment after the End of the Study
Not applicable .
H9X-MC-B021(b) Clini calProtocol Page 32
LY21892657.8.1. Special Treatment Considerations 
Not applicable. 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999565] igator ident ifiesa pati entwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be excluded fro m the study .
8.2. Discontinuation from the Study
Patients will be discont inued in the fo llowing ci rcumstances:
Enrollment in any ot her clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
Participation in the study  needs to be stopped for medical, safet y, regul atory, 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce
Investigator decision
oThe invest igator decides that the patient should be discontinued from the 
study
Subject decision
oThe patientor the patient’s designee, for example , parents or l egal 
guardi anrequests to be withdrawn from the study
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AEand other 
safet y follow-up per Secti on 9.2(Adverse Events) and Section 9.4(Safety) of this protocol.
8.3. Lost to Follow -Up
Not applicable because thi s is a 1- time interview study  and no addi tional study  visits are 
requi red.  
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999566] ivitiesfor this crossover study  for each of the study  phases.  
All outcome assessments will be administered in both phases, except the pi[INVESTIGATOR_32731] i nterview 
question
swill only  be administered during the pi[INVESTIGATOR_731717] .  
9.1. Outcome Assessments
9.1.1. Primary /Secondary Assessments
After parti cipants have been trained and used both devic es, they  will then complete a Global 
Preference Item about whi ch device they prefer ( Appendix 17 ) to evaluate the pr imary objective .  
Specifically , partici pants will be asked, “ Overall, which device do y ou prefer? ”  Parti cipants will 
also be asked to explain why they  selected their response for Ozempic, Trulicit y, or no 
preference.
Parti cipants will then complete the 10-item DID- PQ to evaluate the gated secondary object ive, 
which is based on Item 9 of the DID -PQ(i.e., overall ease of using the injection device) .  The 
DID-PQ compare sthe dulagl utide and semaglut ide devices head -to-head in terms of a variet y of 
device c haracteri stics (for example , ease of preparing the inject ion device, time it takes to 
prepare and inject each dose of medicat ion, confidence that y ou are using the inject ion device 
correctly , and overall convenience of using the injection device) ( Appendix 18 ).
9.1.2. Appropriateness of Assessments
[IP_ADDRESS]. Supplemental Questions
In addit ion to the Global Preference Item, the DID -PQ, and the [ADDRESS_999567] ions will be included in the survey to elicit 
patients’ percept ions of T2DM treatment using injectable agents ( Appendix 11 ).  The 
Suppl emental Quest ions developed for this study  are based on previous items used in the article 
by [CONTACT_731777] . (2018) .  The first question will be administered to participants before t he device 
trainings and will determine the participants’ “willingness to use a di abetes m edicat ion that 
requi red an inject ion for each dose. ”  The second and third Supplementa lQuesti ons will be 
administered to the participants after all the trainings, moc k inject ions, and other study  measures 
have been co mpleted.  Questions S2 and S3 will ask participants specifically about their 
willingness to use the Ozempic and Trulicit y devices, respectively ( Appendix 21 ).  Responses to 
these quest ions will be used to determine patients’ willingness to use each of the devices after 
being trained on both.
[IP_ADDRESS]. Time -to-Train Observer Recording Sheet
For the TTT intervie ws, the study  staff member observing and timing behind the 1-way mirror at 
the interview facilit ies will record the start and end times of the key  training steps for each 
device ( Appendix 13 ).
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999568] ions on age, sex, ethnicit y, living situat ion, em ployment, educati on level, and 
other health condit ions (Appendix 14 ).
[IP_ADDRESS]. Interviewer Recording Sheet
The trained interviewer will use the Interviewer Recording Sheet to document each participant’s 
rando mizat ion order and whether or not the participant was able to complete each of the device 
trainings.  If the participant was shown the device, but did not complete the actual device 
training, the interviewer should explain what happened on this sheet (Appendix 15 ).  
[IP_ADDRESS]. Pi[INVESTIGATOR_731718], once the participants have completed both trainings and mock inject ions 
on the practi ce pad, the participants will be administered a series of interview quest ions about the 
training procedures ( Appendix 16 ).  These intervie w questi ons will  guide the discussion with the 
participants to determine the final training approach to use during the main phase .  
[IP_ADDRESS]. Global Preference Item
All participants will complete the Global Preference Item after being trained and using both 
devices (Appendix 17 ).  Participants will be asked, “ Overall , which device do y ou prefer?”  
Interviewers will then ask p articipants to explain why  they  selected their response for Ozempic, 
Trulicit y, or no preference.  The interviewer will transcribe the participant’s response using 
quotati on m arks to capture the respondent’s exact words.  The Global Preference Item was 
developed specifically for use in thi s device preference mult icenter crossover study .  To hel p 
participants remember the devices more accurately, colored images of the devices have been 
inserted into the questionnaire .  
[IP_ADDRESS]. Diabetes Injection Device – Preference Questionnaire 
The Di abetes Inj ection De vice –Preference Quest ionnaire ( DID-PQ) was designed for the 
purpose of assessing patient preferences between [ADDRESS_999569] ion devices (Appendix 18 ) 
(Matza et al. 2018a ).  On the DID-PQ, each item is rated on a 5-point scale allowing pat ients to 
indicate whether they  prefer or strongly  prefer one of the devices over the other.  For each item, 
patients m ay also respond by  [CONTACT_731778] “no preference” (i.e., neutral) response option, 
indicat ing that they  have no preference between the 2 devices.   
Specifically, for this study , the 
DID-PQ response options will be: Strongly  Prefer Ozem pic De vice, P refer Ozempic Device , 
Strongly P refer Trulicit yDevice, P refer Trulicit yDevice, or have No P reference.   To help 
participants remember the devices more accurately, colored images of the devices have been 
inserted into the questionnaire .  
[IP_ADDRESS]. Four Items from the Medication Delivery Device Assessment 
The original  MDDAB was adapted from insulin- specific quest ionnaires and has been modified 
for use in both inject ion-naïve and non -insulin requiring part icipants (Ma tfin et al. 2015).  Four 
items selected fro m the MDDAB (Matfin et al. 2015; Yu et al. 2017) will be asked of the 
participants about each of the devices under invest igation in this study  (Ozem pic device -specific 
questions: Appendix 19 ; Trulicit y device -specific questions: Appendix 20 ).  These addit ional 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999570] 3 questions ask participants how easy or difficult it was to: (1) learn to use the device,
(
2) to follow the instructi ons when using the device ,and (3) o verall, how difficult or easy was 
the device to use?  The last question asks participants to “Please check the number that best 
indicates how willing you are to continue using the device ”on a scale from 1 (
“Defini tely 
Unwilling ”)to 5(“Definitely Willing ”).  These items will be used in the validat ion of the 
DID-PQ, specifically to assess construct validit y of the DID -PQ by  [CONTACT_731779].  
[IP_ADDRESS]. Clinical Informa tion Form
AClinical Informat ion Form will be com pleted by [CONTACT_731780] (Appendix 22 ).  This form includes a quest ion to document the 
patients’ T2D Mdiagnosis date , the current oral medications the pat ient is taking to treat their 
T2DM ,and the patients’ most recent HbA1c value and date this value was measured .  
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the pati
ent.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are seri ous or otherwi se medically  important, considered rel ated to the invest igational 
product or the study , or that caused the patientto discontinue the invest igational product before 
completing the study.  The patientshoul d be f ollowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
After the informed consent form issigned, study  site personnel will record via designated data 
transmissio n methods the occurrence and nature of each pat ient’s preexist ing condit ions, 
including clinically significant signs and symptoms of the disease under treatment in the study.   
In addi tion, site personnel will record any  change in the condi tion(s) and any new condit ions as 
AEs. Invest igators should record their assessment of the potential relatedness of each AE to 
protocol  procedure, invest igational device , via designated data transmis sion methods .
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure ,and the AE.
The invest igator answers yes/no when making this assessment.
H9X-MC-B021(b) Clini calProtocol Page 37
LY2189265Planned surgeries and non -surgical intervent ions shoul d not be reported as A Es unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational device is discont inued as a result of an AE, study  site personnel  
must report this to Lill y or its designee via designated data transmissio n methods , clar ifying if 
possible, the circumstances leading to any  dosagemodificati ons, or di scontinuati ons of  
treatm ent.  
The appropri ate AE reporting procedures will be followed for each device under in vestigation in 
this study .  
9.2.1. Serious Adverse Events
A serious adverse event ( SAE )is any AE fro m this study  that resul ts in one of the fo llowing 
outcom es:
Death
Initial or prol onged inpat ient hospi [INVESTIGATOR_3094]
Alife-threatening experience ( i.e., immediate risk of  dying)
Persistent or si gnificant disabilit y/incapacit y
Congenital ano maly/birth defect
Important m edical events that may not be immediately  life-threatening or result in 
death or hospi[INVESTIGATOR_82340] m ay jeopardi ze the patient or m ay require interve ntion 
to prevent one of the other outcomes listed in the definit ion above.   Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency room  or at hom e, blood dy scrasias or convulsions that do not 
resul t in inpatient hospi [INVESTIGATOR_3094], or the development of drug dependency  or drug 
abuse.
When a condi tion related to the inject ion pens necessitates medical or surgical 
intervent ion to preclude either perm anent impai rment of  a body  functi on or 
perm anent dam age to a body structure, the seri ous outcom e of “requi red 
intervent ion” will be assigned.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_999571] addit ional data collected using the 
designated data transmissio n methods.
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999572] 
discontinued and/or completed the study  (the patientdisposit ion case report form )has been 
completed).  However, if the investigator learns of any SAE, including a death, at any  time after 
a subject has been discharged fro m the study , and he/she considers the event reasonably possibly  
related to the stud y treatm ent or study  parti cipat ion, the invest igator must prompt ly notify Lilly.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are seri ous events that the 
investigator identifies as related to investigational product or procedure.  [LOCATION_002] 21 CFR 
312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the associated detailed 
guidances or nati onal regulatory  requi rements in parti cipat ing countries require the reporting of 
S[LOCATION_003]Rs. Lilly has procedures that will be fo llowed for the ident ificat ion, recording ,and 
expedited reporting of S[LOCATION_003]Rs that are consistent with global regulat ions and the associated 
detailed guidances.
9.2.2. Adverse Event Monitoring with a Systematic Questionnaire 
Not applicable because this is a device preference study ,and no active drug will be administered 
as pati ents will  not be injecting themselves.  
9.2.3. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery  system s used in 
clinical studies in order to ensure the safet y of study  parti cipants, to monitor qualit y, and to 
facilitate process and product improvements.
Patients will be instructed to contact [CONTACT_221043] /she has a com plaint 
or probl em with the investi gational product or drug delive ry system so that the situation can be 
assessed.
The appropri ate product com plaint reporting procedures will be fo llowed for each device under 
investigat ion in this study .  
9.3. Treatment of Overdose
Not applicable .
9.4. Safety
Refer to Section 10.3.4 .
9.4.1. Electroc ardiograms
Not applicable. 
9.4.2. Vital Signs
Not applicable. 
H9X-MC-B021(b) Clini calProtocol Page 39
LY21892659.4.3. Laboratory Tests
Laboratory  tests are not required and will not be taken for this study  as thi s is a device preference 
study .  The protocol template language for this section is not applicable for this study .
9.4.4. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Hepatic Safety Monitoring
Not applicable.
9.5. Pharmacokinetics
Not applicable .
9.6. Pharmacodynamics
Not applicable .
9.7. Pharmacogenomics or Genetics
9.7.1. Sample sfor Pharmacogenetic Research
Samples o f whole blood and/or saliva are not required and will not be taken for this study  as this 
is a device preference study .  The protocol template language for this sect ion is not appli cable for 
this study .  
9.8. Biomarkers and Other Analyses
Samples o f serum , plasma, urine, cerebral spi[INVESTIGATOR_872], who le blood RNA, whole blood for 
epi[INVESTIGATOR_731719], etc. are not required and will not be taken for this study  as thi s is a device preference 
study .  The protocol template language for this section is not applicable for this study . 
9.9. Health Economics or Medical Resource Utilization and Health 
Economics
Not applicable.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999573] equal  preference for either dulagl utide or 
semaglutide pen (50% of  patients prefer dulaglut ide pen and 50% prefer semaglutide pen) , a 
sample size of 260 patients will provide 90% power against alternat ive hypothesis that there is a 
preference with 60% of the patients choosing the dulaglut ide pen over the semaglutide pen.
Calculation is carried out using 2-sided chi-square test (normal a pproximat ion)at 0.05 level of 
significance.  Software used is Nquery + nTerim 4.0.  Assuming that approximately 10% will not 
provi de any preference information by [CONTACT_731781] “no preference ”optionon the Global 
Preference Item , [ADDRESS_999574] which takes into account the order the device is used as well as 
the cho ice of “no preference” provi desapproximately 90% power against the alternat ive 
hypothesis of 54% choosing dulaglutide pen, 10% indicat ing no preference , and the remaining 
36% choosing semaglut ide pen. This is based on simulat ion of [ADDRESS_999575].
10.2. Populations for Analyses
For purposes of analysis, the following po pulations are defined:
Population Description
Randomized Participants determined to be eligible and then assigned to one of 2 
device order groups (50% will be randomized to use the dulaglutide 
device first, while the other half will use the semaglutide device first).  
More details about randomization for this study are provided in 
Section 7.2.
Evaluable Participants for whom device preference can be evaluated:
Randomized participants who are exposed to both devices (i.e., 
participant was shown both devices via demonstration, regardless of 
whether they successfully complete the training) and complete the 
Global Preference Item.
Withdrawn Partici pants who withdraw from the study before being exposed to both 
devices and completing the Global Preference item.  Details on study 
withdrawal are provided in Section 8.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Evidera.  The statist ical analyses are 
summarized by  [CONTACT_731782](s)in Table 1.1.  
Statistical analyses will be conducted on the evaluable pat ient populat ion (i.e., patients who 
provi de a response to the Global Preference Item) .  
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999576] ical tests will  be p<.[ADDRESS_999577] ificat ion for making the change, 
will be described in the clinical study  report (CSR) .  A more detailed descript ion of this 
statistical analysis will be provided in a statist ical analysis plan (SAP) , and a dditional 
exploratory  analyses of the data may be conducted as deemed appropriate.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
A detailed description o f patient di sposi tion w ill be provided at the end of the study . 
[IP_ADDRESS]. Patient Characteristics
Descript ive statistics will summarize demographics, clinical characteristics, and pat ient-reported 
outcom e (PRO) measures. Continuous variables will be summarized wit h means, standard 
deviat ions, ranges, and minimum and maximum values.  Categorical variables such as gender 
and race will be presented in terms of frequencies and percentages.  Demographics, clinical 
characterist ics, and PRO data will be presented by  [CONTACT_731783] .  
[IP_ADDRESS]. Concomitant Therapy 
Not applicable.  
[IP_ADDRESS]. Treatment Compliance
Not applicable.  
10.3.3. Statistical Analyses
[IP_ADDRESS]. Primary Analyses
The primary  analysis of this study  will evaluate the results of the G lobal Pref erence Item  (i.e., 
Overall, which device do y ou prefer?) to examine whether there is a difference in preference 
between the dulaglutide device and the semaglut ide device.  The Prescott test will be run to 
determine whether there is a statisticall y significant difference in preference between the devices, 
while controlling for order effects.  The preference results (for example , counts, percentages and 
95% confidence interval [ CI]) will also be presented.   The qualitat ive data capturing reasons for
the response to the Global Preference Item will also be presented .  
[IP_ADDRESS]. Gated Secondary Analyses
The gated secondary  analysis of this study  will be conducted if the primary  objective i s found 
statist ically significant. The analysis will co mpare the dulaglut ide and semaglut ide devices wit h 
regard to ease of use.  Responses to the 5-point response scale of DID -PQ Item 9 (Overall  ease 
of use) will be co llapsed into 3 categories.  The “strongly prefer” and “prefer” response options 
will be co mbined for each devi ce, resul ting in 3 categori es: prefer dul aglut ide, prefer 
semaglutide, and no preference.  Then, the Prescott test will be run to examine whether there is a 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999578] ically significant difference in preference between the devices, while controlling for order 
effects.  Data from global Item 9 on the DID -PQ will also be presented to illustrate the “ease of 
use” responses by [INVESTIGATOR_16897] (for example , counts, percentages ,and 95% CI) .  
The complete scoring guide for the DID -PQ will be presented in the SAP for this study .  
[IP_ADDRESS]. Exploratory Analyses 
[IP_ADDRESS].1. Exploratory 1.  DID -PQ Analyses of Items 1 to 8 and 10
Exploratory  anal yses of Items 1to 8 and 10 of the DID -PQ will fo llow the same procedures as 
those for the gated secondary  objective described above. 
[IP_ADDRESS].2. Exploratory 2.  Time -to-Train Analyses 
Exploratory  analysis [ADDRESS_999579] each device will 
be re ported.  
[IP_ADDRESS].3. Exploratory 3.  Supplemental Question Analyses 
Using the data from the [ADDRESS_999580] ions(i.e., S1. Would you be willing to use a 
diabetes m edicati on that requi red y ou to give y ourself an injection for each dose?; S2. How 
willing would y ou be to use the Ozempic inject ion device? ; and S3. How willing would you be 
to use the Trulicit y injection device?), descriptive analyses will be run to examine willingness to 
use each of the devices after being trained on both.  Descript ive statistics wi ll be reported for 
each i tem (i.e., frequencies, percentages).  
[IP_ADDRESS].4. Exploratory 4.  Evaluation of the DID- PQ 
Exploratory  analysis 4 will focus on psychometric evaluat ion of the DID- PQ.  The DID -PQ has 
been administered in 2 studi es thus far: the original  psycho metric validat ion study  (Matza et al . 
2017b) and the US study  com paring the dulaglut ide and liraglut ide devices (Matza et al. 2018 a).  
In both studies, the DID -PQ was administered to a relat ively small  subgroup of pati ents who had 
used m ore than [ADDRESS_999581] validit y will be assessed by  
[CONTACT_731758] -PQ responses to responses on 4 items selected from the MDDAB 
H9X-MC-B021(b) Clini calProtocol Page 43
LY2189265(Matfin etal.2015; Yu et al. 2017) .  Cross -tabul ation tables of these 4 items by [CONTACT_731784] -PQ items will be presented.  The 4 items assess (1) ease of learning how to 
use the device, (2) ease of fo llowing instructi ons when using the device, (3) overall ease -of-use, 
and (4) will ingness to continue using the device.
Lastly, the DID -PQ exploratory  approach for comparing devices will be examined relat ive to the 
ancillary  measures (i .e., responses on the 4 items selected from  the MDDAB for each device ).  
This approach to analyzing da ta from the DID -PQ was developed as part of the original 
instrum ent devel opment work, but i t has never before been implemented and evaluated in a 
study .  Am ong pati ents indicat ing a preference for one device over the other, a statistical test can 
be perfor med to determine whether a significant preference exists. This test would assess 
whether the proportion indicat ing preference for oneof the [ADDRESS_999582] yields a si gnificant p -value, then the null 
hypothesis can be rejected, which would mean that significantly more respondents preferred one 
device over the other.
[IP_ADDRESS]. Missing Data
Study  team  members will perform a thorough review of the participants’ ques tionnaires pri or to 
the com pletion of  each interview to minimize missing data.  No imputations will be performed 
for missing data.  If a participant decides to withdraw fro m the study , data collected to the point 
of withdrawal may  be used in analysis to pr eserve the integrit y of the research proj ect.  There 
will be no lost to follow -up data because there is no fo llow
-up peri od in this study .
10.3.4. Safety Analyses
This study  focuses on preference between devices, and no medicat ion will be administered to 
study  participants.  However, if a participant reports an AE related to the study , the appropri ate 
reporting procedures will be fo llowed.  See Section 9.2for more AE details .  
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable as no investigational drug or treatment will be administered during this study .
10.3.6. Evaluation of Immunogenicity 
Not applicable.  
10.3.7. Other Analyses
[IP_ADDRESS]. Health Economics 
Not applicable.
[IP_ADDRESS]. Subgroup Analyses 
Not applicable.  
H9X-MC-B021(b) Clini calProtocol Page 44
LY218926510.3.7.3. Pi[INVESTIGATOR_731720] a content analysis 
approach.  The purpose of the pi[INVESTIGATOR_731721], comprehensible, and feasible prior to the main phase.  
Descript ive statistics ( for example , mean, standard deviat ion, frequency) will be used to 
summarize the sample in terms of sociodemographic c haracteri stics and on the other measures 
completed by  [CONTACT_731785] (i .e., Gl obal Preference Item, DID -PQ, 4 items selected fro m the 
MDDAB for each device).  
A content analysis approach will be used to analyze the responses collected on the pi[INVESTIGATOR_731722] q uestions.  This content analysis applies only  to the pil ot phase.  Responses will be 
examined to determine answers to the fo llowing questions for each device:
Are there any ways the device training could be easier or more clear?  If y es, 
please explain. 
Would you recommend any  changes to the device training procedures?  If y es, 
please explain.
How m uch addi tional guidance is appropriate and useful during the device 
training?
During the pi[INVESTIGATOR_32731], the principal invest igator and study team will be cont inuously mo nitoring 
the interview and data as they are collected to determine if changes need to be implemented 
immediately .  If major changes are requi red, Evi dera and Lilly will determine if the pi[INVESTIGATOR_731723].  Upon conclusio n of the pi[INVESTIGATOR_32731], Evidera study  staff will 
send to Lilly  a summary  document of the pil ot phase, which will serve as the interim analysis.  
The pi[INVESTIGATOR_731724] 10 to 20 participants will not be included i n the final 
sample of approximately 290 pat ientswith T2DM .  
10.3.8. Interim Analyses
Not applicable.
H9X-MC-B021(b) Clini calProtocol Page 45
LY218926511. References
Aroda VR, Henry  RR, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ. Efficacy of 
GLP -1 receptor agonists and DPP -4 inhibitors: meta -analysis and sys temati c review. Clin 
Ther . 2012;34(6):1247-1258. e1222.
Asakura T, Suzuki S, Aranishi T, Cai Z. Co mparative usabilit y study  of the dul aglut ide single -
use pen versus the insulin degludec FlexTouch® among self -inject ion-naïve patients wi th type 
2 diabetes mel litus in Japan. Curr Med Res Opin . 2018 ;34(6) :1117-1124.
Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Once -weekly  
dulaglut ide versus bedt ime insulin glargine, both in co mbination wit h prandial insulin lispro, 
in patients with t ype 2 diabetes (AWARD -4): a randomis ed, open -label, phase 3, non -
inferi ority study . 
Lancet . 2015;385(9982):[ADDRESS_999583] T, Gonz ález JG, At isso C, Sealls W, Fahrbach JL. 
Once -weekly dulaglut ide versus once -daily  liragluti de in metformin -treated pati ents wi th type 
2 diabetes (AWARD -6): a randomis ed, open -label, phase 3, non -inferiorit y trial. Lancet . 
2014;384 (9951):1349 -1357.
Dungan KM, Weitgasser R, Perez Manghi F, et al. Pi[INVESTIGATOR_731725] E, Fahrbach JL, Jiang HH, Shell J, 
Robertson KE. A 24 -week study to evaluate the efficacy and safet y of once -weekly dulaglut ide 
added on to glimepi[INVESTIGATOR_731726] t ype 2 diabetes (AWARD -8).Diabetes Obes Metab . 
2016;18(5):475 -482.
Edwards KL, Minze MG. Dulaglut ide: an evidence -based review of its potential in the treatment 
of type 2 di abetes. Core Evid. 2015;10:11-21.
Eli Lilly and Company . Instructi ons f or Use: TRULICITY® (Trū -li-si-tee) (d ulaglut ide) 
inject ion, for subcutaneous use –0.75 mg/0.5 mL Single -Dose Pen once weekly. Original: 
2014; Updated: November 16, 2017. Available at:http://pi.lilly.co m/us/trulicit y-lowdose -ai-
ifu.pdf .
Gelhorn HL, Bacci ED, Poon JL, Boy e KS, Suzuki S, Babin eaux SM. Evaluating preferences for 
profiles of glucagon -like pept ide-1 receptor agonists among injection -naïve type 2 di abetes 
patients in Japan. Patient Prefer Adherence . 2016;10:1337 -1348.
Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS . Evaluat ing preferences 
for profiles of GLP -1 receptor agonists among injection -naïve type 2 diabetes pati ents in the 
[LOCATION_006]. Patient Prefer Adherence . 2015;9:1611-1622.
Giorgino F, Benroubi  M, Sun JH, Zimmermann AG, Pechtner V. Efficacy  and safety  of 
once -weekly dulaglut ide versus insulin glargine in patients with type 2 diabetes on met formin 
and glimepi[INVESTIGATOR_14956] (AWARD -2). Diabetes Care . 2015;38(12):2241-2249.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR; American Diabetes Associat ion (ADA); European Associat ion 
for the Study  of Diabetes (EASD). Management of hyperglycemia in t ype 2 diabetes: a 
patient-centered approach: posit ion statem ent of  the American Diabetes Associat ion (ADA) 
and the Euro pean Association for the Study  of Diabetes (EASD). Diabetes Care . 
2012;35(6):1364 -1379.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999584], Khunt i K, Davies MJ. Efficacy and safet y of 
glucagon -like peptide -1 receptor agonists in t ype 2 diabetes: a system atic review and 
mixed -treatm ent com parison analysis. Diabetes Obes Metab . 2017;19(4):524 -536.
Khunt i K, Gomes MB, Pocock S, Shestakova MV, Pi[INVESTIGATOR_731727] S, Fenici P, Hammar N, Medina J. 
Therapeut ic inertia in the treatment of hyperglycaemia in pat ients with type 2 di abetes: a 
system atic review. Diabetes Obes Metab . 2018;20(2):[ADDRESS_999585] e with type 2 diabetes treate d with basal insulin. 
Diabetes Obes Metab. 2016;18(4):401 -409.
Khunt i K, Sei du S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy
and outcom esin type 2 diabetes : a meta-analysis. Diabetes Care . 2017;40(11):1588-1596.
Khunt i K, Wo lden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inert ia in people wit h 
type 2 di abetes: a retrospective cohort study  of more than 80,[ADDRESS_999586] e. Diabetes Care. 
2013;36(11):[ADDRESS_999587] DB, Milicevic Z. Dulagluti de as add -on therapy  to SGLT2 inhibitors in patients 
with inadequately  controlled ty pe 2 diabetes (AWARD -10): a 24 -week, randomis ed, 
doubl e-blind, placebo -controlled tr ial. Lancet Diabetes Endocrinol . 2018;6(5):[ADDRESS_999588] ive use of the 
once weekly dulaglutide single -dose pen in injection -naïve patients with t ype2 diabetes . J 
Diabetes Sci Technol . 2015;9(5):[ADDRESS_999589] ion devices used with dulaglutide and liraglut ide for treatm ent of Ty pe 2 
diabetes. Curr Med Res Opin . 2018a;24(8) :1457-1464 .
Matza LS, Boy e KS, Jordan J, Norrbacka K, Gent ilella R, Tiebout A, Brown C, Federici MO, 
Stewart KD. Patient preferences in Italy : Heal th state utilit ies associated with attributes of 
weekly inject ion devices for treatm entof type
2 diabetes . Patient Pref Adhere nce. 2018b ; 
12:971-979.
Matza LS, Boy e KS, Stewart KD, Davies EW, Paczkowski R. Health state utilit ies associated 
with attributes of weekly inject ion devices for treatment of type 2 diabetes. BMC Health Serv 
Res. 2017a;17(1):774.
Matza L, Stewart K, Paczko wski R, et al. Validat ion of a quest ionnaire to assess patient 
percepti onsof inject ion devices for type
2 diabetes . ISPOR 22ndAnnual Internat ional Meet ing; 
[LOCATION_011], MA; May 20-24, 2017b.
Nauck M, Weinstock RS, Umpi[INVESTIGATOR_81089], Guerci B, Skrivanek Z, Milicevic Z. Efficacy  and 
safet y of dulaglut ide versus sitaglipt in after 52 weeks in type 2 diabetes in a randomized 
controlled trial (AWARD -5). Diabetes Care . 2014;37(8):2149 -2158.
[NICE] National  Institute for Health and Care Excellence. Ty pe 2 di abetes: the management of 
type 2 di abetes. NICE Clinical Guideline 87. London, [LOCATION_006] ; Issued: May 2009 ; Last Modified: 
December 2014:54.
H9X-MC-B021(b) Clini calProtocol Page 47
LY2189265Norrbacka A, Stein D, Matza L, Jordan J, García -Pérez L, Hassan S, Boy e K. Time to treatm ent 
intensificat ionwith GLP -1 receptor agonists for patients with type 2 diabetes in the [LOCATION_006]: 
Medical Record Review Study . 54thAnnual Meet ing of the European Association for the 
Study  of Diabetes (EASD); [LOCATION_010]; October 1-5, 2018.
Novo Nordisk. Instructions for Use: OZEMPIC® (semag lutide) inject ion, for subcutaneous use –
0.5 m g/1 m g. Ini tial US Approval : 2017; Revised: December 2017; 13 p.
Poon JL, Boy e KS, Thieu VT, Norrbacka KN, Hassan SW, Gelhorn HL.Preferences for 
attributes of medicationsamong patients with type 2 diabetes: a cross- medication class 
comparison of inject ion therapi[INVESTIGATOR_014] . Curr Res Diabetes Obes J . 2018;6(5):555700.
Pozzilli P, Norwood P, Jodar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. 
Placebo -controlled, randomized trial o f the addi tion of  once -weekly glucagon -like pept ide-[ADDRESS_999590] dulaglutide to titrated daily insulin glargine in pat ients with type 2 diabetes 
(AWARD -9). Diabetes Obes Metab . 2017;19(7):1024 -1031.
Trujillo JM, Nuffer W, Ellis SL. GLP -1 receptor agonists: a review of head -to-head clinical 
studi es. Ther Adv Endocrinol Metab. 2015;6(1):[ADDRESS_999591] DB, Botros 
FT. Dulaglut ide versus insulin glargine in patients with type 2 diabetes and moderate -to-severe 
chronic kid ney disease (AWARD -7): a multic entre , open -label, rando misedtrial. Lancet 
Diabetes Endocrinol . 2018 ;6(8):605 -617.
Umpi[INVESTIGATOR_124012] G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy  and safet y 
of dulaglut ide monotherapy  versus m etformin in t ype 2 di abetes in a rando mized controlled 
trial (AWARD -3). Diabetes Care . 2014;37(8):2168-2176.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M. 
Efficacy and safet y of dulagl utide added onto pi[INVESTIGATOR_731728] 2 di abetes in a rando mized controlled trial (AWARD -1). Diabetes Care . 
2014;37(8):2159 -2167.
Yu M, Van Brunt K, Milice vic Z, Varnado O ,Boye KS. Patient -reported outcom e resul tsof 
dulaglut ideadded to titrated insulin glargine in patients with type 2 diabetes (AWARD -9).
Clin Ther . 2017;39:2284 -2295.
H9X-MC-B021(b) Clini calProtocol Page 48
LY218926512. Appendices
H9X-MC-B021(b) Clini calProtocol Page 49
LY2189265Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorabl e 
and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
CI confidence interval
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
Com pliance Adhe rence to all study -related, good clinical practice, and applicable regulatory 
requirements.
DID-PQ Diabetes Injection Device –Preference Questionnaire
Enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
Enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GLP-1 Glucagon -like peptide -1
HbA1c glycosylated hemoglobin A1c
HCP health care provider
IFU instructio ns for use 
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study , after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
[CONTACT_3553] a written, signed ,and dated informed consent form.
Investigational device The investigational devices in this study will include the 2 devices under investigation 
(i.e., Ozempic and Trulicity) that are being evaluated in this multicenter crossover 
device preference study.  
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999592] of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study. 
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TTT time-to-train
T2DM type 2 diabetes mellitus
H9X-MC-B021(b) Clini calProtocol Page 51
LY2189265Appendix 2. Study  Governance Considerations
Appendix 2.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 2.1.1.Informed Consent
The Evidera investigator and research staff are r esponsible for the following:
Ensuring that the patient understands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their participat ion is vo luntary.
Ensuring that informed consent is given by  [CONTACT_731786] l egal representati ve.  
This includes obtaining the appropriate signatures and dates on the in formed 
consent form (ICF) prior to the performance of any  protocol  procedures and pri or 
to the administration of invest igational product.
Answering any quest ions the patient may have throughout the study ,and sharing 
in a timely  manner any  new inform ation that may be relevant to the patient’s 
willingness to continue his or her participat ion in the study .
Ensuring that a copy  of the ICF is provi ded to the parti cipant or the participant’s 
legal representative and is kept on file.
Ensuring that the medical rec ord includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the date 
when the wri tten consent was obtained.  The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 2.1.2.Recruitment
For the pi[INVESTIGATOR_32731], Evidera is responsible for the central recruit ment strategy  for participants.
For the main phase, the clinical sites are responsible for the central recruit ment strategy  for 
patients.  Indivi dual invest igators may have addit ional local requirements or processes.
Appendix 2.1.3. Ethical Review
The invest igator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by [CONTACT_178363] (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Eli Lilly and 
Com pany ( Lilly )before the study  may begin at the invest igative site(s).  Lilly or its 
representatives must approve the ICF, including any changes made by [CONTACT_41429], before it is used 
at the investigative site(s).  All ICFs must be compliant with the ICH guideline on Good Clinical 
Practi ce (GCP).
The study ’s ERB(s) should be provided with the following:
H9X-MC-B021(b) Clini calProtocol Page 52
LY2189265The protocol  and rel ated am endments and addenda, and updates during the 
course of the study ;
ICF;
Other rel evant docum ents (for example, curricula vitae, advertisements) .
Appendix 2.1.4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the following :
Consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational Organizat ions
ofMedical Sciences Internat ional Ethi cal Guidelines ;
Applicable ICH GCP Guidelines ;
Applicable laws and regulations .
The sponsor (Lilly), Evidera invest igator, and Evidera research staff are responsible for adhering 
to any  regu lations and/or laws pertinent to using and transferring the devices for clinical trial use.
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 2.1.5. Investigator Information
Physicians with a specialt y ininternal  medicine ,endocrinol ogy, or primary  care/f amily doctors
will part icipate as invest igators in this clinical trial.
Appendix 2.1.6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her kno wledge, the protocol accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 2.1.7. Final Report Signature
[CONTACT_731798]’s responsible medical o fficer and statistician will approve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study .
Appendix 2.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Evidera will do the fo llowing:
Provide instructi onal material to the study  sites, as appropriate ;
Sponsor start -up training to instruct the investigators an d study  coordinators.  This 
training will give instruction on all study  recrui tment procedures ;
Be available for consultation and stay  in contact [CONTACT_57999] h the study  site personnel  by 
[CONTACT_2319], tel ephone, and/or fax ;
H9X-MC-B021(b) Clini calProtocol Page 53
LY2189265Train Evidera staff to deliver the standardized trainings on both devices following 
the Intervi ew and Device Training Guide ( Appendix 12 );
Review and evaluate Case Report Form (CRF)data and use standard computer 
edits to detect errors in data collection ;
Conduct a qualit y review of the database .
Data collect ion will be conducted according to the protocol and will progress according to the 
study  procedures previ ously  outlined in Section5.5.
At the time of enrollment, participants will be assigned unique ident ificat ion numbers.  The 
unique identifiers assigned will be used to track the participants throughout the study .  Only  the 
unique participant ident ification and participant initials will be entered into the database and 
recorded on the participant questionnaires —not parti cipant nam es.
Parti cipants will be assured of the confidential nature of the interview.  If, at any  time, 
participants beco me unco mfortable with a questi on or the process, they will be given the option 
of terminat ing the study interview.  All interviews will take place in a quiet and private space to 
ensure confident iality.  Evi dera study  staff will  review all  forms for com pleteness pri or to 
concl uding the study  visit.  
Only Evidera staff for the pi[INVESTIGATOR_731729],will know the identit y of the 
participants.  Study  staff will  be instructed to m aintain com plete c onfident iality of all co llected 
data.  For both study  phases, trained Evidera interviewers and research support staff will observe 
the interviews, and have access only to de -ident ified data on the study  CRFs.  Lilly  empl oyees 
may also observe so me of the s tudy interviews.  
Extensive procedures for the careful and co mplete collect ion of data will be implemented by [CONTACT_731787] .  At the com pletion of each interview, study  staff will check every  page 
of each quest ionnaire to ensure that no i tems were unintent ionally  skipped.  Parti cipant 
recrui tment will be mo nitored on a regul ar basis throughout the study  using tracking logs.  The 
Evidera Principal Invest igator and Qualit y Assurance Analyst will be available for consultation 
regarding study  implementation, recruit ment, and any other queries throughout this process.
The study  may be audi ted by  [CONTACT_731788], and/or regulatory  agencies at any  time.  
Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  If requested, the investigator will 
provi de the sponsor, applicable regulatory  agencies, and applicable ERBs with direct access to 
original  source docum ents.
Appendix 2.2.1. Data Capture System
For data collect ion, Evidera will use DataFax, a data m anagement sy stem  that relies on opti cal 
character recognition so ftware ,for collect ing study data.  The CRFs for this study  will be 
formatted f or the DataFax system.  DataFax improves data qualit y through qualit y control reports 
and autom atic queries, while increasing speed and efficiency o f data collection.  When the data is 
H9X-MC-B021(b) Clini calProtocol Page 54
LY2189265received, the system ident ifies any problems wit h the data, and queries are automat ically 
generated.  Evidera will implement this data entry  process and prepare the data verificat ion 
guidelines.  
For both the pi[INVESTIGATOR_731730], Evidera will be responsible for the fo llowing:
Entering and cleaning all data collection forms in DataFax;
Storing all the original patient-completed CRFs.  Retaining records for a 
minimum o f 2 years on -site and an addi tional 5 years off -site in storage ;
Managing the completed data, performing qualit y checks, and merging all 
participant datasets;
Following good research practice guidelines; and
Adhering to all procedures outlined in the protocol.
Evidera will maintain the originals of all patient-completed CRFs and t he clinical sites will  
maintain the originals of all site-completed CRFs.   However, for the main phase , sites will 
provi de Evidera scanned copi[INVESTIGATOR_731731] n/Exclusion Forms in advance of all study  
interviews to confirm pat ients’ eligibilit y.  Sites will  also provi de Evidera scanned copi[INVESTIGATOR_731732]-completed Clinical Information Forms.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 2.3. Study and Site Closure
Appendix 2.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or Evidera, the invest igator, or the ERB of 
the study  sitejudges it necessary for medical , safety, regulatory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 2.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or Evidera judges i t necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 2.4. Publication Policy
The publicat ion policy for Study  H9X -MC-B021 is described in the study  proposal .
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999593] never used self -injected medication , you may be eligible 
to participate in this study.
We are looking for people to take part in a 90–120 minute interview about 
diabetes medication.  The study does not involve treatments.  We are 
interested in your opi[INVESTIGATOR_6153].  Study visits will be held in -person in [location].
Participants will receive <$insert amount> for their time.
Please CALL Evidera at [to be inserted (free phone)] and leav e a message with your name [CONTACT_731799] E-MAIL with your name [CONTACT_731800] [to be inserted].
Ref # [ZIP_CODE]

H9X-MC-B021(b) Clini calProtocol Page 56
LY2189265Appendix 4. Pi[INVESTIGATOR_731733] ( Evidera ) –Pi[INVESTIGATOR_731734] [XXXX], and I conduct research at Evidera, an independent healt hcare research 
company.  Thank y ou for responding to our advertisement about the diabetes research study .
The goal of this interview study  is to determine patient preferences for two type 2 di abetes 
treatm ent devices current ly co mmercialized .  Your experience with t ype 2 diabetes can help us in 
this process.
If you qualify  and choose to parti cipate, y ou woul d be asked to attend a 90 –120 minute 
individual, in -person interview wi th anEvidera researcher interviewer at [locati on].  You will 
not receive treatment wit h any  drugs during thi s study . During the interview, y ou will be trained 
on how to use two inject ion devices that are currently co mmercialized .  You will be asked to 
perform  mock inject ions using both devices on a pad, and then asked to complete a series o f 
questionnaires related to y our condi tion and the use of the devices.  The amount of time it takes 
for an interviewer to train y ou to use each device will be recorded.
The informat ion that y ou provi de in the interview will be kept as confidential as possible.  A 
study  identification number will be assigned to the informat ion you give and y our name [CONTACT_731801].
There are minimal risks to participat ing in the st udy because of being trained and performing 
mock injecti ons on pads wi th devices.  For example, y ou coul d have an accidental needle st ick
injury .  
All interviewers have been trained on how to handle any issues that may arise fro m using 
the devices.  During all interviews, a medical pro fessional (e.g., nurse or paramedic) will be on 
site in case of adverse events such as unant icipated needlest icks.  Participat ion is ent irely 
voluntary.  You are free to withdraw from the study  at any  time. 
For y our time and participat ion, you will receive <$insert amount> , whi ch will  be given to y ou 
in the form of a Greenphi re ClinCard that is used just like a credit card .
Would you be interested in part icipating?
  No -Thank him/her for his/her time and consideration.
  Yes -Continue with the script.
That’s great!  To find out if you are eligible to participate, I need to ask a few questions.  The 
inform ation you give will be kept as confident ial as possible.  You do not have to answer 
questions y ou do not want to, bu t that m ay disqualify  you.
H9X-MC-B021(b) Clini calProtocol Page 57
LY2189265ELIGIBILITY SCREENING
Note to screener:  Please complete the follow ing inclusion/exclusion criteria table for each 
participant.  Certain inclusion/exclusion criteria may not be determined via phone screen (e.g., 
cognitive ability to understand the device trainings ).  For these criteria, the final eligibility 
determination w ill be established at the time of the interview .
ELIGIBILITY CRITERIA Answer Fits criteria?
1. What is y our age?  Age:  _______ [If less than 18 years 
old,not eligible.]Yes    No
2. Have you been diagnosed 
with type 2 diabetes ?  If yes, 
in what year were y ou 
diagnosed?  Yes , record diagnosis year:  _______
  No [not eligible, terminate]Yes    No
3.  Have y ou been diagnosed 
with type 1 diabetes ?   Yes [not eligible, terminate]
  No Yes    No
4.  Are y ou currently  pregnant?
  Yes [not eligible, terminate ]
  No [continue to 5] Yes    No
5.  Have y ou ever been on self -
injectable therapy (e.g., 
diabetes therapi [INVESTIGATOR_731735])?  Yes [not eligible, terminate]
  No Yes    No
6.  Have y ou ever administered 
injectable treatment (e.g., 
diabetes therapi [INVESTIGATOR_731735]) to others?  Yes [not eligible, terminate]
  No Yes    No
7.  Are y ou a health care 
practitioner that is trained in 
giving inject ions?  Yes [not eligible, terminate]
  No Yes    No
H9X-MC-B021(b) Clini calProtocol Page 58
LY2189265ELIGIBILITY CRITERIA Answer Fits criteria?
8.  Do y ou currently receive
oral treatm ent for your ty pe 2 
diabetes?  Yes, which one(s)?: _____________
_________________________________
  No [not eligible, terminate]Yes    No
9.  Are y ou able to bring proof 
of your oral treatment 
prescription for type 2 
diabetes to the interview ? 
(e.g., the medicat ion itself, 
the medicat ion packaging, a 
prescri ption note, or a letter 
from your doctor) .  Yes
  No [not eligible, terminate]Yes    No
10.  Are y ou willing and able to 
attend an in -person 
interview ?  Yes
  No [not eligible, terminate]Yes    No
11.  Do y ou feel that y ou are able 
to read, speak, and 
understand English 
sufficiently to fully 
participate in an interview 
and co mplete questionnaires?  Yes
  No [not eligible, terminate]Yes    No
12.  Are y ou willing and able to 
provide written informed 
consent ?  Yes
  No [not eligible, terminate]Yes    No
13.  Are y ou currently enrolled 
in any other clinical study 
involving an investigational 
product ?  Yes [not eligible, terminate]
NoYes    No
14.  Have y ou parti cipated, 
within the last [ADDRESS_999594]?  Yes [not eligible, terminate]
  NoYes    No
H9X-MC-B021(b) Clini calProtocol Page 59
LY2189265ELIGIBILITY CRITERIA Answer Fits criteria?
15.  Are y ou an Eli Lilly and 
Company, Novo Nordisk, 
Evidera, or [COMPANY_003] 
(Pharm aceut ical Product 
Development) employee ?   Yes [not eligible, terminate]
  NoYes    No
Respondents must be able to attend interview  and meet all the required criteria.  Otherw ise, the 
respondent is NOT ELIGIBLE to participate.
H9X-MC-B021(b) Clini calProtocol Page 60
LY2189265ELIGIBILITY RATING
Based on the eligibility responses above, the respondent is:
  Not Eligible -I’m sorry , but based on y our responses I’m not able to include y ou in the 
study .  Thank y ou for your time.  [Terminate call]
  Eligible -Based on what y ou have tol d me, y ou are eligible to participate in the study .  
Can I ask y ou som e addi tional questi ons?
Proceed with gathering additional demographic information from eligible & interested 
participants.
ADDITIONAL DEMOGRAPHIC 
INFORMATION
1.  What is y our gender ?    Male    Female
2a.  What is your ethnic background?  1  Hispanic or Latino
2  Not Hispanic or Latino
3  Not applicable
2b.  What is y our raci al background? 
(check all that apply )1  Amer ican Indian or Alaska Nat ive
2  Asian
3  Black or African American
4  Native Hawaiian or Other Pacific Islander
5  Whit e
6  Other: _________________________________
3.  What is y our current em ployment 
status?  Full -time work
  Part-time work
  Homemaker/housewife
  Student
  Unemplo yed
  Retired
  Disabled
  Other:  ______________________
4.  Where did y ou find out about thi s 
research study?
  Newspaper Ad:  ______________
  Other:  _____________________
Thank y ou for provi ding m e with this inform ation.
We are also being asked to pass on to the study  sponsor any  details o f adverse events and product 
complaints that are m entioned during this research study . Although this is a 1-time interview 
and what y ou say  will, of course, be treated i n confidence, sho uld you m ention an adverse event 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999595] device complaint, the study  team  will need to report this even if it has already been 
reported by  [CONTACT_731789]. 
Are y ou willing to proceed with the interview?
  Yes (conti nue)
  No (terminate) 
Based on the answers y ou just gave m e, you are able to parti cipate in this study .  Are y ou able to 
come [insert interview location] for an in -person intervi ew? 
  Yes (continue)
  No (terminate)
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999596] these interviews over a period of [roughly two weeks in Month ], so we 
are looking for dates that y ou m ay be available.  If one of the dates that y ou are available is 
selected, we will contact y ou soon to confirm that y ou are still interested and available on the 
selected date and time.  We will then send y ou di rections to the interview location.
Schedule Interview
Participant Name
[CONTACT_731802]/        /
   DD / MMM / YYYY_____:_____ AM/PM
time
Phone NumbersPlease check the box with the preferred number
  Home ________________________
  Work _______________________
  Cell ________________________
Best times to call:  
________________________________________
Information for sending a 
confirmation letter with 
directions to the interviewWe need to send y our interview confirmat ion via e -mail or 
regul ar mail with directions to the interview.  In addit ion, 
closer to the interview y ou will receive a reminder phone call.  
Please be aware that if y ou share an e -mail account with 
someone else, they  may be able to read the information that we 
send.  How would y ou prefer to receive y our interview 
inform ation?
E-mail confirmat ion (Ask participant to provide e -mail 
address): 
_____________________________________________
Regular mail confirmat ion (Ask participant for mailing 
address to send via regular mail):
_____________________________________________
_____________________________________________
Screener Name: ___________________________________________
H9X-MC-B021(b) Clini calProtocol Page 63
LY2189265Screener Signature: ___________________________________  Date: ____/______/______
                        DD MMM  YYYY
H9X-MC-B021(b) Clini calProtocol Page 64
LY2189265Appendix 5. Pi[INVESTIGATOR_731736]/Exclusion Criteria
INCLUSION/EXCLUSION CRITERIA FORM 
(EVIDERA STUDY STAFF) – PI[INVESTIGATOR_731737]: 
INCLUSION CRITERIA YES NO
1. Participant is ≥18 years of age  
2. Participant has been diagnosed with type 2 diabetes  
3. Participant is self -injection naïve to all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731738])  
4. Participant is injection naïve to performing all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731739]) to others  
5. Participant is currently receiving oral treatment for their type 2 diabetes  
6. Participant is willing and able to attend an in -person interview  
7. Participant is able to read, speak, write, and understand the English language  
8. Participant is willing and able to provide written informed consent  
If ANY of the above answers are NO, the parti cipant is NOT ELIGIBLE for parti cipat ion in 
this study . Do not proceed any further with this participant . If ALL of the above i tems are 
YES , continue.
Please assess the exclusio n criteria by [CONTACT_731790]:
EXCLUSION CRITERIA YES NO
Study staff should use recruitment/screening interaction to assess these questions:
1. Currently diagnosed with gestational diabetes and/or type 1 diabetes  
2. Currently pregnant  
3. Cognitive or physical difficulties that could interfere with ability to understand the training, 
perform the injection tasks, or complete the study questionnaires as judged by [CONTACT_093] 
4. Currently enrolled in any other clinical study involving an investigational product or any other 
type of medical resear ch judged not to be scientifically or medically compatible with this study 
5. Has participated, within the last [ADDRESS_999597]  
6. Is a health care practitioner who is trained in giving injections  
7. Is an Eli Lilly and Company, Novo Nordisk, Evidera, or [COMPANY_003] employee  
If ANY of the above answers to the exclusio n questi ons are YES; the participant is NOT 
ELIGIBLE for parti cipation in this study .
CONSENT
H9X-MC-B021(b) Clini calProtocol Page 65
LY21892651. Parti cipant has provi ded written consent: Yes    No
2. Date consent obtained:__ __/__ __ __/__ __ __ __
   DD      MMM      YYYY
INVESTIGATOR SIGNATURE [CONTACT_81619]
I certify  that the above informat ion is correct.
Investigator/Designee 
Signature:____________________________________________ __/__ __ __/__ __ __ __
   DD      MMM      YYYY
H9X-MC-B021(b) Clini calProtocol Page 66
LY2189265Appendix 6. Confirmation Letter /E-mail
PARTICIPANT CONFIRMATION LETTER /E-MAIL –PI[INVESTIGATOR_8571] & MAIN PHASE
[Date for letter]
[Parti cipant Nam e and Address for letter]
Dear [Parti cipant]:
Thank y ou for your interest in our research study .  We appreciate y ou taking the time out of y our 
schedule to participate in our interview.  We have scheduled y our in -person interview at <Time> 
on <Date> at <locat ion name [CONTACT_3816]>.  We h ave included driving direct ions and [public 
transport sy stem ] directions to this facilit y with this [letter or e -mail].  
The purpose of this study  is to better understand patients’ preferences for diabetes treatm ents.  
For thi s study , we are interviewing peopl e with type [ADDRESS_999598] approximately [pi[INVESTIGATOR_32731] : 1.5 to 2 hours; main phase: 1 to 1.5 hours ].  
[For pi[INVESTIGATOR_731740] :  Please remember to bring proof of y our ty pe 2 di abetes oral  
medicat ion(s) with y ou to the interview (e.g., the medicat ion itself, the box the medication co mes 
in, or a l etter from  your doctor).]  After y our interview, y ou will be com pensat ed a specified 
amount for your time and travel to the study interview [pi[INVESTIGATOR_32731] :<
$insert amount> ; main 
phase : <$insert amount >].  
Upon arrival to the <location>, please <to provide instructions for checking in and proceeding to 
interview room >.  If y ou have any  questi ons or concerns, please call [pi[INVESTIGATOR_32731]: Evidera
contact [CONTACT_731791] ; main phase :Clinical site contact [CONTACT_731792] e and 
telephone number] .  Thank y ou again for y our interest in this study .  We greatly appreciate y our 
participat ion.
Sincerely, 
[pi[INVESTIGATOR_32731]:   Evidera contact [CONTACT_731793], tit le]
[main phase:   Clinical sitecontact [CONTACT_731793], title]
H9X-MC-B021(b) Clini calProtocol Page 67
LY2189265Appendix 7. Reminder Phone Call/ E-mail
PARTICIPANT REMINDER PHONE CALL – PI[INVESTIGATOR_8571] & MAIN PHASE
Hello [Insert Participant Greeting]
My name [CONTACT_832] [XXXX], from [pi[INVESTIGATOR_32731] : Evidera; main phase : Clinical site name] . I am just 
calling to remind y ou that y ou are scheduled to take part in a one -on-one interview at <Time> on 
<Date> at <Location name [CONTACT_3816]>.  [For pi[INVESTIGATOR_731740] :  Please remember 
to bring proof of you r type 2 diabetes oral medication(s) w ith you to the interview  (e.g., the 
medication itself, the box the medication comes in, or a letter from your doctor).]   
Full details o f the study  have been previously e -mailed or sent to y ou by  [CONTACT_447].
Will you be able to attend?  [If no, please try  and re -schedule the participant.]
PARTICIPANT REMINDER E -MAIL –PI[INVESTIGATOR_731741] [Insert Participant Greeting]:
You are scheduled to take part in a one- on-one interview at <Time> on <Date> at <Location 
name [CONTACT_731803]>.  The interview will last approximately  [pi[INVESTIGATOR_32731] : 1.5 to 2 hours; main 
phase: 1 to 1.5 hours].  [For pi[INVESTIGATOR_731740] :  Please remember to bring proof of 
your type 2 diabetes oral medication(s) w ith you to the interview  (e.g., the m edication itself, the 
box the medication comes in, or a letter from your doctor).]   
Please respond to this e -mail wit h confirmat ion that y ou are still able to attend.
Full details o f the study  have been previously e -mailed or sent to y ou by  [CONTACT_447]. 
[pi[INVESTIGATOR_32731]:   Evidera contact [CONTACT_731793], tit le]
[main phase:   Clinical site contact [CONTACT_731793], title]
H9X-MC-B021(b) Clini calProtocol Page 68
LY2189265Appendix 8. Main Phase Screening Script
Screening Script (Clinical Site) –Main Phase
The Inclusio n/Exclusio n Cri teria Form  is a separate form but there are criteria that can be 
reviewed by  [CONTACT_731794]. Before you introduce the research 
study to the patient please confirm using the patient’s medical chart:
1. Patient is ≥18 years of age   Confirmed
2. Patient has been diagnosed with T2DM   Confirmed
3. Patient is self -injection naïve to all injectable treatment (e.g., diabetes 
therapi[INVESTIGATOR_731742])  Confirmed
4. Patient is currently receiving oral treatment for their type 2 diabetes   Confirmed
Once all above criteria have been confirmed, please conduct recruit ment with patient according 
to the following script.  Please com plete the Inclusio n/Exclusio n Cri teria Form .
Hello, thi s is [name] fro m [clinic]. We are currently recruit ing patients with t ype 2 diabetes to 
participate in a research study  being conducted by  [CONTACT_731761], a heal th outcom es research 
organi zation. The goal of the interview study is to determine patient preferences for the ty pe 2 
diabetes t reatment devices currently co mmercialized.  
If you qualify  and choose to parti cipate, y ou woul d be asked to attend a 60 -90 minute individual, 
in-person interview with a nEvidera researcher at [locat ion].  You will not receive treatment with 
any drugs duri ng this study .  During the interview, y ou will be trained on how to use two 
inject ion devices current ly co mmercialized .  You will be asked to perform mock inject ions using 
both devices on a pad, and then asked to complete a series of quest ionnaires related to your 
condi tion and the use of the devices.
[For Time -to-Train Participants:   The am ount of t ime it takes for an interviewer to train y ou to 
use each device will be recorded.]  
The informat ion that y ou provi de in the interview will be kept as confident ial as possible. A 
study  identification number will be assigned to the informat ion you give and y our name [CONTACT_731801].  The informat ion you share during the interview will not be shared with y our 
doctor, and will have no impact on the care that y ou receive or y our abilit y to parti cipate in 
future studies.
There are minimal risks to participat ing in the study because of the use of being trained and 
performing mock inject ions on pads with devices.  For example, you coul d have an accidental 
needle st ick injury .  All  interviewers have been trained on how to handle any issues that may 
arise fro m using the devices.  During all interviews, a medical pro fessio nal (e.g., nurse or 
param edic) will be on site in case of a dverse events such as unant icipated needlest icks.  
Parti cipation is ent irely vo luntary.  You are free to withdraw from the study  at any  time. 
H9X-MC-B021(b) Clini calProtocol Page 69
LY2189265For y our time and parti cipat ion, youwill receive: <$insert amount> (via Greenphire ClinCard).
Are you intereste d in participating?
  No –Thank them for their time and considerat ion.
  Yes –Great. Now, to find out if you are eligible for this study , I need to ask a few 
questions.
Confirm any inclusion/exclusion criteria w ith the patient that cannot be ascertain ed based on the 
chart/information using the Inclusion/Exclusion Criteria Form .
If not eligible:   Thank you for y our interest in the study , however y ou are not eligible to 
participate.
If eligible, continue.
We are also being asked to pass on to the study  sponsor any  details o f adverse events and product 
complaints that are m entioned during this research study .  Although thi s is a 1- time interview 
and what y ou say  will, of course, be treated i n confidence, should y ou m ention an adverse event 
or product devic e com plaint the study  team  will need to report thi s even if it has already been 
reported by  [CONTACT_731789].
Are y ou happy to proceed wi th the intervi ew on this basis?
  
Yes (continue)
  No (terminate) 
Based on the answers y ou just gave m e, you are able to parti cipate in this study .  Are y ou able to 
come [insert interview location] for an in -person intervi ew? 
  Yes (continue)
  No (terminate)
If in-person, continue:
What i s the best day  and time for y ou to com e in to com plete the interview? 
[Schedule for interview ]
Parti cipant Ini tials:  _______
Name [CONTACT_731804] :  _________________________________
Interview Date :  __________________ Time :  ___________
For all interviews, continue:
May I have y our e -mail, mailing address and/or phone numbers?  We will need this informat ion 
to con tact y ou in the future as we arrange the scheduling of the interviews and/or to remind y ou 
about y our intervi ew (Please remind participant that if they share an e -mail address w ith 
someone, that individual may be able to read the information that we send ).
H9X-MC-B021(b) Clini calProtocol Page 70
LY2189265  Yes (proceed with asking for con tact inform ation)
  No (Skip to bottom  of script and give participant [y our si te] contact [CONTACT_3031])
What i s the best phone number to use? 
Patient Name: ________________________
Address: 
____________________________________
____________________________________
____________________________________Please check the box with the preferred number
  Home ________________________
  Work _________________________
  Cell __________________________
Best times to call:  
_________________________________________________
_______________________
E-mail address: 
____________________________________ _____________
_______________________
Please remind participant that if they share an e -mail address 
with someone else, this other person may be able to read the 
information that we send. 
If you have any quest ions or if you would like to cancel/reschedul e your intervi ew, please 
contact [ clinic staff name ] at [ clinic staff number ]. Thank you very much for y our time.  Have a 
nice day!
Screener Name: ___________________________________________
Screener Signature:  ___________________________________  Date: ____/______/______
            DD  MMM  YYYY
H9X-MC-B021(b) Clini calProtocol Page 71
LY2189265Appendix 9. Main Phase Inclusion/Exclusion Criteria
INCLUSION/EXCLUSION CRITERIA FORM (CLINICAL SITE) –MAIN PHASE
Please review the participant’s eligibilit y. Check YES or NO for each of the fo llowing cri teria: 
INCLUSION CRITERIA YES NO
1. Patient is ≥18 years of age  
2. Patient has been diagnosed with type 2 diabetes  
3. Patient is self -injection naïve to all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731739])  
4. Patient is injection naïve to performing all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731743]) to others  
5. Patient is currently receiving oral treatment for their type 2 diabetes  
These questions will need to be asked of the patient to see if he or she is eligible:  
6. Are you self -injection naïve to all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731738])? 
7. Are you injection naïve to performing all injectable treatment (e.g., diabetes therapi[INVESTIGATOR_731739]) to others? 
8. Are you willing and able to attend an in -person interview?  
9. Do you feel that you are able to read, speak, write, and understand English sufficiently to 
fully participate in an interview and complete questionnaires? 
10. Are you willing and able to provide written informed consent?  
If ANY of the above answers are NO, the parti cipant is NOT ELIGIBLE for parti cipat ion in 
this study .  Do not proceed any further with this participant .  If ALL of the above i tems are 
YES , continue.
Please assess the exclusio n criteria by [CONTACT_731790]:
EXCLUSION CRITERIA YES NO
Clinic site should use the patient’s medical record and the recruitment/screening interaction to 
assess these questions:
1. Currently diagnosed with gestational diabetes and/or type 1 diabetes  
2. Currently pregnant  
3. Cognitive or physical difficulties that could interfere with ability to understand the training, 
perform the injection tasks, or complete the study questionnaires as judged by [CONTACT_1275] 
4. Currently enrolled in any other clinical study involving an investigational product or any 
other type of medical research judged not to be scientifically or medically compatible with 
this study 
5. Has participated, within the last [ADDRESS_999599] 
6. Is a health care practitioner who is trained in giving injections  
H9X-MC-B021(b) Clini calProtocol Page 72
LY2189265EXCLUSION CRITERIA YES NO
7. Investigator, site personnel, or immediate family member of investigator or site 
personnel.  (Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.) 
8. Is an Eli Lilly and Company, Novo Nordisk, Evidera, or [COMPANY_003] employee  
If ANY of the above answers to the exclusio n questi ons are YES; the participant is NOT 
ELIGIBLE for parti cipation in this study .
CONSENT
1. Parti cipant has provi ded written consent: Yes    No
2. Date consent obtained:__ __/__ __ __/__ __ __ __
   DD      MMM      YYYY
INVESTIGATOR SIGNATURE [CONTACT_81619]
I certify  that the above informat ion is correct.
Investigator/Designee Signature:
____________________________________________ __/__ __ __/__ __ __ __
   DD      MMM      YYYY
H9X-MC-B021(b) Clini calProtocol Page 73
LY2189265Appendix 10. Participant Recruitment Tracking Log
Please send the Recruitment Tracking Log to Evidera every [insert day of the week] 
(Attn: XXXX at 301-654- 9864 or e -mail: [insert e -mail address])
Screening 
IDInitials Eligible Participant 
AgeParticipant 
GenderParticipant 
IDInterview Date and Time
(DD/MON/YYYY; time)All Reasons Ineligible or 
Withdraw
Example
S01-001ABCY 
N 35 FExample
101-[ZIP_CODE]/NOV/2018; 9:[ADDRESS_999600]
Example 
S01-002 DEFY 
N 60 MExample
101-[ZIP_CODE]/NOV/2018; 11:[ADDRESS_999601]
Example 
S01-003GHIY 
N 55 F N/A N/A Ineligible (Inclusion #3)
Example 
S01-004JKLY 
N 17 F N/A N/AIneligible (Exclusion #1 
and 3)
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999602] ion for each dose?
  Not willing
  Somewhat not willing
  Neutral
  Somewhat willing
  Very willing
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999603] ion Pens (one for demonstration and one for participant use)
6.Sharps container (for disposal o f Trulicit y Devices and Ozempic Needles)
7.Inject ion pad
8.Alcoho l wipes
9.Trash can (for pen cap)
10.Non-latex gloves
II. INTERVIEW STEPS
1.Confirm the in/ex form  has been co mpleted
2. Inform ed consent 
3.Com plete Suppl emental  Quest ion S1 
4.Randomization wit h IWRS system to determine which device is first
5.Explain study  to the parti cipant
6.First Device: Training and Mock Inject ion
7.Com plete dem ographic form
8.Second Device: Tr aining and Mock Inject ion
9.Com plete Intervi ewer Recording Sheet
10.Com plete questi onnaires about devi ce preferences and Supplemental Quest ions S2 and 
S3
STEP 1 . CONFIRM IN/EX FORM HAS BEEN COMPLETED
Review the site- completed in/ex form for the participant to confirm eligibilit y.  
This form  shoul d be provi ded to y ou by  [CONTACT_4179], and i t shoul d already  be com pleted pri or 
to the interview. 
STEP 2 . INFORMED CONSENT
Review the consent form wit h the parti cipant and confi rm com prehensio n.  
Provi de the parti cipant wi th opportuni ty to answer questions before signing.
Ask the participant to sign two copi[INVESTIGATOR_731744].  
H9X-MC-B021(b) Clini calProtocol Page 76
LY2189265Countersign the forms and provide a copy  to the parti cipant. 
STEP 3 . COMPLETE SUPPLEMENTAL QUESTION S1
Ask the participant to independently co mplete this question: “Please co mplete this 
question, and let me know when y ou are finished.” 
STEP 4 . RANDOMIZATION WITH IWRS SYSTEM
Com plete the randomizat ion process to determine the order of device training for the 
participant. 
Record the order on the Interviewer Recording Sheet. 
STEP 5 . EXPLAIN THE STUDY TO THE PARTICIPANT
“You will be trained to use two devices for inject ing medicat ion for type 2 di abetes. ” 
“For each device, I will walk you through the steps for using each device and 
demonstrate the steps for y ou.  Then, you will use the device to administer an inject ion 
into an inject ion pad.” 
“After y ou have had a chance to use both devices, I will ask you to com plete som e 
questionnaires that ask about y our preference between the devices.” 
“Do not inject medication into yourself.  You will only be injecting into the injection 
pad.”  
“Please handle the devices carefully  to avoi d accident ly sticking y ourself with the needle.  
If you appear to be handling the device incorrectly , I will try  to correct y ou so y ou do not 
accidently st ick yourself wit h the needle.” 
STEP [ADDRESS_999604] DEVICE TRAINING
Follow the Trulicit y Training Guide or the Ozempic Training Guide based on the randomizat ion 
order for the participant. 
STEP 7 . DEMOGRAPHIC FORM
“Please complete this form.”
STEP 8. SECOND DEVICE TRAINING
Follow the Trulicit y Training Guide or the Ozempic Training Guide based on the randomizat ion 
order for the participant. 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999605] the participant to com plete questi onnai res on device preference and supplemental 
questions S2 and S3 .
H9X-MC-B021(b) Clini calProtocol Page 78
LY2189265Ozempic Training Guide
A. Time to Train
The observer should co mplete the TTT Observer Recording Sheet.
a.Start of the training (i.e., after reading the IFU )
b.The parti cipant pi[INVESTIGATOR_731745]. 
c.The parti cipant successfully  injects the m edicat ion into the inject ion pad and removes the 
needle/device from the pad.
d.The Ozempic pen is recapped with the pen cap (the inner needle cap a nd outer needle cap 
shoul d not be pl aced back on the pen) .
e.The parti cipant has com pleted the inject ion and finished asking questions.  Participants 
comments/opi[INVESTIGATOR_731746] a question. 
B. Safety Procedures
If the participant appears to be making an error that could lead to self -harm, the trainer should 
immediately  intervene and stop the inject ion process.
C. Introduction
Introduce the device and training steps.
“Now, you will  learn to use an inject ion device.”
“When y ou feel comf ortabl e with the procedures for using the device, y ou will use the 
device to perform a mock inject ion into the injection pad.”
“You should NOT use this device to inject y ourself.  You will only be inject ing 
medicat ion into this pad.”
“This is the Ozempic device .  This device is used to administer medicat ion once a week, 
and you woul d typi[INVESTIGATOR_153795] i t at hom e.”(Show  the device to the participant .)  
D. Device Training
1.Open the device box and place the IFU in front of the participant.
2.Instruct the participant to “Please read the Instructions for Use and let me know when y ou 
are finished.  After y ou are done reading, I will demo nstrate all o f these steps for y ou in 
detail.  You can also refer back to this document throughout the interview as much as you 
want.”
H9X-MC-B021(b) Clini calProtocol Page 79
LY21892653.Dem onstrate the injection process using the demo device. 
1.“The Ozempic device is a prefilled dial-a- dose pen .  You can select doses of 0.[ADDRESS_999606] ion today .”
2.“The needles for this device are enclo sed in the package.” 
3.“Always use a new needle for each injection .”
4.Device parts
a.“This is the pen cap .”
b.“This is the pen window .” 
c.“This is the dose counter and dose pointer .” 
d.“This is the dose sel ector and the dose button .”
e.“When y ou turn the dose selector, y ou will see the flow check symbol  and the dashed 
line to gui de to y our dose ( turn dose selector to show  these symbols ).  The flow check 
symbo l comes right after the zero .”
f.“The needle has an outer needle cap, inner needle cap, needle, and paper tab. ”
5.Step 1: Prepare your pen with a new needle
a.“If you were inject ing, y ou woul d begin by  [CONTACT_14390] y our hands with soap and water. 
Since y ou are inject ing a pad today, you do not need to wash your hands this time.”
b.“The next step is to check the name [CONTACT_731805] m ake sure that 
it contains Ozempic.”
c.“Then pull off the cap .”
d.“Check that the Ozempic in your pen is clear and colorless . Look through the pen 
windo w.  If the Ozempic is cloudy , do not use the pen.”
e.“Take a new needle , and tear off the paper tab.”
f.“Push the needle straight on to the pen.  Turn until it is on tight .”
g.“Pull off the outer needle cap .  You can put it in the sharps container .”
H9X-MC-B021(b) Clini calProtocol Page 80
LY2189265h.“Pull off the inner needle cap , and throw it away .”
6.Step 2: Check the Ozempic flow with each new pen
a.“Check the Ozempic flo w before y our first injection with each new pen.”
b.“Turn the dose selector until the dose counter shows the flow check symbol .”
c.“Hold the pen wit h the needle po inting up.  Press and hold in the dose button until 
the dose counter shows 0.  The [ADDRESS_999607] from me.”
d.“If no drop appears , repeat these flow check steps up to six more times.  Do not use 
the pen if a drop of Ozempic st ill does not appear.”
7.Step 3: Select your dose
a.“Turn the dose selector until the dose counter shows your dose (0.25 mg) .  If you 
select the wrong dose, y ou can turn the dose selector forward or backwards to the 
correct dose.” 
8.Step 4. Inject your dose
a.“Choose y our inject ion site.”
b.“Insert the needle into your skin [injection pad ].”
c.“Make sure you can see the dose counter .  Do not cover i t with your fingers.  This 
could stop the inject ion.”
d.“Press and hold down the dose button until the dose counter shows [ADDRESS_999608] 
line up with the dose pointer.  You may then hear or feel a click.”
e.“Keep the needle in your skin [injection pad] after the dose counter has returned to 
0 and count slowly to 6 .”
f.“If the needle is removed earlier, y ou m ay see a stream  of Ozempic coming from the 
needle t ip.  If this happens, the full dose will no t be delivered.”
g.“Remove the needle from your skin [injection pad ].”
9.Step 5. After your injection
a.“Carefully twist the needle off of the pen.   Since we have a sharps container, 
please do not put the needle caps back on the needle to avoid needle st icks.”
H9X-MC-B021(b) Clini calProtocol Page 81
LY2189265b.“Place the needle in a sharps container right away .”
c.“Put the pen cap on your pen after each use to protect Ozempic fro m light.”
4.Permi t the participant to ask any quest ions they  may have about the device or IFU.
“Do y ou have any quest ions about the steps invo lved in the inject ion process?”
“Do y ou feel ready  to administer the m ock inject ion?Is there any thing y ou woul d like to 
review before trying it ?”
When the patient is ready: “I will leave the instructions for use here, and you can refer to 
them as m uch as y ou like while y ou go through the injection process.  Please take all the 
time y ou need.”
5.Parti cipant performs m ock inject ion into the inject ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
6.The m ock inject ion will be considered complete when the patient has successfully performed 
all critical steps listed below and recapped the pen.  
7.
If the participant is struggling to remove the needle and appears to be putting themselves at 
risk of an accidental needle st ick, the interviewer should vo lunteer to rem ove the needle for 
them. 
“Woul d you like me to rem ove the needle for y ou?”
If the interviewer removes the needle, this should be recorded on the Interviewer Recording 
Sheet. 
8.If the participant does not dispose of the needle in the sharps container independent ly, the 
trainer should instruct the participant on disposal using the provi ded sharps container.
“Please place the needle in the sharps container.”
9.Ask the participant if they have any  questi ons, and answer them.  The training is complete 
when there are no further questions. 
“Do y ou have any quest ions?”
E. Checklist to as sist interviewer in tracking critical steps
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999609] 
attemptFourth 
attemptFifth 
attempt
1.Pull o ff the pen cap □ □ □ □ □
2.Push the needle straight on to 
the pen.  Turn unt il it is on 
tight.□ □ □ □ □
3.Pull o ff the outer needl e cap 
and pull o ff the inner needle 
cap□ □ □ □ □
4.Turn the dose selector until the 
dose counter shows the flow 
check symbo l□ □ □ □ □
5.Press and ho ld the dose button 
until the dose counter shows 0 
and a drop of Ozempic appears 
at the needle tip□ □ □ □ □
6.If the drop does not appear on 
the first attempt, repeat flow 
check unt il a drop appears ( up 
to 6 times ).□ □ □ □ □
7.Select y our dose. Continue 
turning the dose selector un til 
the dose counter shows 0.25□ □ □ □ □
8.Insert the needle in the pad □ □ □ □ □
9.Press and ho ld down the dose 
button until the dose counter 
shows 0□ □ □ □ □
10.Slowly  count to 6 
(operati onally: pat ient pauses 
after pressing inject ion button). □ □ □ □ □
11.Remove the needle from  the 
pad□ □ □ □ □
12.Remove the needle from the 
pen (capped or uncapped)□ □ □ □ □
F. Retraining
If the critical steps are not performed c orrectly on the first attempt, the participant should be 
retrained on crit ical steps that were missed or performed incorrectly.  The participant mayhave 
to repeat all or some of the inject ion process.   The error should be explained to the participant 
and the participant should be asked to make the correction and cont inue the inject ion process . 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999610]. “It looks like the inner cap is still on.  Could you remove the inner cap before checking the 
flow?”
H9X-MC-B021(b) Clini calProtocol Page 84
LY2189265Trulicity Training Guide
A. Time to Train
The observer should co mplete the TTT Observer Recording Sheet.
a.Start of training (i.e., after reading the IFU)
b.The parti cipant pi[INVESTIGATOR_731745]. 
c.The parti cipant successfully  injects the m edicat ion into the inject ion pad and removes the 
needle/device from the pad.
d.The Trulicit y pen is dropped into the sharps container.
e.The parti cipant has com pleted the inject ion and finished asking questions.  Participant 
comments/opi[INVESTIGATOR_731747] a question. 
B. Safety Procedures
If the participant appears to be making an error that could lead to self -harm, the trainer should 
immediately  intervene and stop the inject ion process.
C. Introduction
Introduce the device and training steps.
“Now, you will  learn to use an inject iondevice.”   
“When you feel co mfortable with the procedures for using the device, y ou will use the 
device to perform a mock inject ion into the injection pad.” 
“You should NOT use this device to inject y ourself.  You will only  be inject ing 
medicat ion into this pad.”
“This is the Trulicit y device .  Thi s device is used to administer medicat ion once a week, 
and you woul d typi[INVESTIGATOR_153795] i t at hom e.”(Show  the device to the participant .)  
D. Device Training
1.Open the device box and place the IFU in front of the participa nt.
2.Instruct the participant to “Please read the Instructions for Use and let me know when y ou are 
finished.  After y ou are done reading, I will demo nstrate all o f these steps for y ou in detail.  
You can al so refer back to this document throughout the inte rview as much as y ou want.”
3.Dem onstrate the injection process using the demo device. 
H9X-MC-B021(b) Clini calProtocol Page 85
LY21892651.Before you get started
a.“Check the pen label to make sure y ou have the ri ght m edicine and i t has not 
expi[INVESTIGATOR_5697].”
b.“Inspect the pen to make sure i t is not dam aged”
c.“Inspect the m edicine to make sure i t is not cl oudy or di scolored, and it should not 
have particles in it.”
d.“If you were inject ing yourself, y ou woul d then wash y our hands .  Since y ou are 
inject ing a pad today , you do not need to wash y our hands this time. ”
e.“If you were inject ing yourself, y ou woul d select an injection site .  Today , you will 
inject into this injection pad and NOT into y our body .” 
2.Device parts
a.“At the top of the device, there is a green inject ion button .”
b.“Beneath that is a lock ring, and an indicator which lines up with the lock and unlock 
symbo ls.”
c.“Down here y ou can see the m edicine .”
d.“At the bottom, y ou can see the clear base and the base cap .”
e.“The needle is inside the device.”
3. Steps for injection
a.Uncappi[INVESTIGATOR_731748]. 
i)“You woul d first m ake sure the pen is locked ” 
ii)“Then pull the base cap straight off and throw i t away  in the trash”. 
iii)“Do not put the base cap back on –this coul d damage the needle.”
b.Second, place the base on the inject ion site and unlock the device
i)“You woul d place the cl ear base flat and firmly against y our skin (or in this case, 
the inject ion pad).” 
ii)“Unlockby [CONTACT_480767]”.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999611] ion
i)“You woul d press and ho ld the green inject ion button .  You will hear a loud 
click .” 
ii)“When y ou press the button, the medicat ion is injected .”
iii)“Continue to hold the clear base firmly against the pad until y ou hear a second 
click .  This happens when the needle starts retracting in about 5 –10 seconds.  My 
demo device may  be slower than the actual device you use, so listen closely for 
the click on y our devi ce.” 
iv)“Then remove the pen from yourskin [ injection pad ].”
v)“You will know the inject ion is co mplete when the gray  plunger i s visible.” 
d.The final step is disposing of the pen.
i)“Put y our used pen in the sharps disposal container right away  after use”.
4.Permi t the parti cipant to ask any  quest ions they  may have about the device or IFU.
“Do y ou have any quest ionsabout the steps invo lved in the inject ion process?”
“Do y ou feel ready  to administer the m ock inject ion?Is there any thing y ou woul d like to 
review before trying it ?”
When the patient is ready: “I will leave the instructions for use here , and y ou can refer to 
them as m uch as y ou like while y ou go through the injectio n process.  Please take all the 
time y ou need.”
5.Parti cipant performs m ock inject ion into the inject ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
6.The m ock inject ion will be considered complete whe n the patient has successfully performed 
all critical steps listed below and placed the device in the sharps container.  
7.If the participant does not dispose of the device in the sharps container independent ly, the 
trainer should instruct the participant on device disposal using the provided sharps container. 
“Please place the pen in the sharps container.”
8.Ask the participant if they have any  questi ons, and answer them.  The training is complete 
when there are no further questions.
“Do y ou have any quest ions?”
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999612] 
attemptFourth 
attemptFifth 
attempt
1.Take off base cap □ □ □ □ □
2.Place on inject ion site □ □ □ □ □
3.Unlock device □ □ □ □ □
4.Press button and ho ld the 
device in place unt il the grey  
plunger is visible. The 
participant shoul d pause. □ □ □ □ □
5.Remove f rom inject ion site □ □ □ □ □
F. Retraining (if necessary)
If the critical steps are not performed correctly on the first attempt, the participant should be 
retrained on crit ical steps that were missed or performed incorrectly.  The participant mayhave 
to repeat all or some of the inject ion process.   The error should be explained to the participant 
and the participant shoul d be asked to make the correction and cont inue the inject ion process. 
If the participant is making a mistake during the inject ion, you can call  their attenti on to the 
mistake so that he or she can continue the injection correctly.  For example, if th e parti cipant i s 
trying to press the inject ion button without unlocking the device, tell the participant to unlock it.  
“It looks like the device is st ill locked.  Can y ou unl ock i t before inject ing?”
H9X-MC-B021(b) Clini calProtocol Page 88
LY2189265Appendix 13. Time -to-Train (TTT) Observer Recording 
Sheet
TTT Observer Recording Sheet
To be com pleted by [CONTACT_731795]:
1. Ozempic
1a. Start time of training (i.e., after reading the IFU ):  0:00
1b. Start time of participant performing mock injection(s):  ______:______ 
1c. End time of successfully administered mock injection (i.e., withdrawal of needle/device from 
injection pad) :  ______:______
1d. End time of mock injection procedures (Ozem pic = recappi[INVESTIGATOR_731748]) : ______:______
1e. End time of training, including all procedures and questions:   ______:______
Num ber of interventions: _______
2. Trulicity
2a. Start time of training introduction (i.e.,after reading the IFU ):  0:00
2b. Start time of participant performing mock injection(s):  ______:______ 
2c. End time of successfully administered mock injection (i.e., withdrawal of needle/device from 
injection pad) :  ______:______
2d. End time of mock injection procedures (Trulicity = disposing of the pen in the sharps 
container) : ______:______
2e. End time of training, including all procedures and questions:   ______:______
Num ber of interventions: _______
H9X-MC-B021(b) Clini calProtocol Page 89
LY2189265Appendix 14. Demographic Form
Demographic Form –Participant Completed
1.  What is y our age?
2.  What is y our gender?   Male     Female
3a.  What is y our ethnic background?
  Hispanic or Latino
  Not Hispanic or Latino
  Not applicable
3b.  What is y our raci al background? ( Please check all that apply )
  Amer ican Indian or Alaska Native
  Asian
  Black or African American
  Native Hawaiian or Other Pacific Islander
  Whit e
  Other:  
4.  What is y our m arital status?
  Single
  Married
  Divorced
  Separated
  Widowed
  Other:  _____________
5.  How would y ou describe y our em ployment status? (Please ti ck all boxes that apply )
  Full -time work
  Part-time work
  Homemaker/housewife
  Student
  Unemplo yed
  Stay-at-home parent
  Retired
  Disabled
  Other:  ______________________
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999613] completed? ( Please check only one )
  Elementary /primary  school
  Secondary/high school
  Some college
  College degree
  Postgraduate degree
  Other:  ______________________________________
7.  Have y ou had any  of the f ollowing healt h conditi ons? (Pl ease t ick/check all boxes that apply )
  Ang ina
  Arthritis
  Cancer 
  Chronic obstructive pulmonary disease/emphysema
  Heart attack or heart disease
  Hypertensio n 
  Stroke
  Depression
  Other mental healt h condit ions (please specify):  ______________________
  Other health condit ions (pl ease specify ): ________________________________
  None
H9X-MC-B021(b) Clini calProtocol Page 91
LY2189265Appendix 15. Interviewer Recording Sheet
Interviewer Recording Sheet
To be completed by [CONTACT_20679]:
1. Device Randomized to First Training:     Ozem pic Device        Trulicit y Device
  Participant completed training for first device
  Participant com pleted training, but required interviewer ’sassistance to remove the needle 
(Ozem pic only)
  Participant was exposed to this device ,but did not complete training.  Please explain below:
_______________________________ ______________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
2. Device Randomized to Second Training:     Ozem pic Device        Trulicit y Device
  Participant completes traini ngfor second device
  Participant com pleted training, but required interviewer assistance to remove the needle 
(Ozem pic only)
  Participant was exposed to this device but did not complete training.  Please explain below:
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_________________________________ ____________________________________________________
_____________________________________________________________________________________
H9X-MC-B021(b) Clini calProtocol Page 92
LY2189265Appendix 16. Pi[INVESTIGATOR_731749] s
Pi[INVESTIGATOR_731750] (select one):
  1. Ozempic Device; 2. Trulicit y Device 2. Trulicit y Device; 1. Ozempic Device
Questions about Ozempic Device:
1.  Are there any ways the Ozempic device training coul d be easier or m ore cl ear?  If  yes, pl ease 
explain.
  No
  Yes , please explain:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
2.  Would yo u recommend any changes to the Ozempic device training procedures?  If yes, please 
explain.
  No
  Yes , please explain:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
3.  How much addit ional guidance is appropriate and useful during the Ozem pic training? 
  Video  
  Interviewer uses demonstration pens to review key device steps
  Interviewer a nswers questions
  Other suggestions?
Please explain response:  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
H9X-MC-B021(b) Clini calProtocol Page 93
LY2189265Questions about Trulicity Device:
1.  Are there any ways the Trulici ty device training coul d be easier or m ore cl ear?  If  yes, pl ease 
explain. 
  No
  Yes , please explain:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
2.  Would you recommend any changes to the Trulicit y device training procedures?  If yes, please 
explain.
  No
  Yes , please explain:
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
3.  How much addit ional guidance is appropriate and usefu l during the Trulicit y training ? 
  
Video  
  Interviewer uses demonstration pens to review key device steps
  Interviewer answers questions
  Other suggestions?
Please explain response:  
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
Thank the participant for taking part in the study.  Ask the participant to refrain from 
discussing the interview with anyone else who plans to take part in the study.
H9X-MC-B021(b) Clini calProtocol Page 94
LY2189265Appendix 17. Global Prefe rence Item
To be completed by [CONTACT_55473]:
1.Overall, which device do you prefer?
  Ozempic   Trulicity   No Preference
To be completed by [CONTACT_86296] :
2.Please explain y our preference indicated in Item 1 on the Global Preference Questi onnai re 
(interviewer to record reasons for device preference provided by [CONTACT_238519], provide 
quotes wi th quotati ons m arks and wri te neat ly):
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999614] only one response for each item to indicate which of the two injection devices you prefer.
Ozempic DeviceTrulicity Device
Strongly Prefer 
Ozempic
DevicePrefer Ozempic 
DeviceNo 
PreferencePrefer
Trulicity 
DeviceStrongly 
Prefer Trulicity 
Device
1.Ease of preparing the 
injection device and 
medication for use    
2.Ease of fitting the 
injection into your 
routine    
3.Ease of bringing the 
injection device with 
you when it is 
necessary to inject 
away from home    
4.Confidence that the 
injection device 
provides the correct 
dose of medication 
every time    
5.Confidence that you 
are using the injection 
device correctly    
6.The size of the needle     
7.The time it takes to 
prepare and inject 
each dose of 
medication    
8.Overall satisfaction 
with the injection 
device     
9.Overall ease of using 
the injection device     
10.Overall convenience of 
using the injection 
device     

H9X-MC-B021(b) Clini calProtocol Page 96
LY2189265Appendix 19. Four Items From MDDA B –Ozempic Device
Four Items From MDDAB –Ozempic Device
Instructions :  Based on your experience with the medication delivery device used in this study, please indicate how easy or difficult 
it was to use the device. For each question, please check the number that best represents your experience with using the device.
How difficult or easy was it to do the following?
Very Difficult DifficultNeither 
Difficult nor 
EasyEasy Very Easy
1.To learn how to use the device 1 2 3 4 5
2.To follow the instructions when using the 
device1 2 3 4 5
3.Overall, how difficult or easy was the device 
to use?1 2 3 4 5
Instructions :  The following question asks you to think about your confidence in continuing to use the device you used in this study.  
Please think about the following question as if you were prescribed this medicine and this device would be available to you after the 
study.

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999615] indicates 
how willing you are to continue using the 
device.1 2 3 4 5
H9X-MC-B021(b) Clini calProtocol Page 98
LY2189265Appendix 20. Four Items From MDDA B –Trulicity  Device
Four Items from MDDAB –Trulicity Device
Instructions :  Based on your experience with the medication delivery device used in this study, please indicate how easy or difficult 
it was to use the device. For each question, please check the number that best represents your experience with using the device.
How difficult or easy was it to do the following?
Very Difficult DifficultNeither Difficult 
nor EasyEasy Very Easy
1.To learn how to use the device 1 2 3 4 5
2.To follow the instructions when using the 
device1 2 3 4 5
3.Overall, how difficult or easy was the device 
to use?1 2 3 4 5
Instructions :  The following question asks you to think about your confidence in continuing to use the device you used in this study.  
Please think about the following question as if you were prescribed this medicine and this device would be available to you a fter the 
study.

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999616] indicates 
how willing you are to continue using the 
device.1 2 3 4 5
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999617] ion device?      
  Not willing 
  Somewhat not willing
  Neutral 
  Somewhat willing 
  Very willing
S3.  How willing would y ou be to use the Trulicit y injection device?       
  Not willing 
  Somewhat not willing
  Neutral 
  Somewhat willing 
  Very willing

H9X-MC-B021(b) Clini calProtocol Page 101
LY2189265Appendix 22. Clinical Information Form
Clinical Information Form –Site Completed
Instructions:  Please com plete the following questio ns for eligible pat ients.
1.When was the patient diagnosed with T2DM?  
If the day  and m onth are unknown, please report the year of diagnosis, and check the box “Day and Month of T2DM diagnosis 
unknown”.
If day is unknown, please report month and year of diagnosis, and check the box “Day  of T2DM di agnosis unknown”.
   
                                
                            D D       M      M      M   Y     Y      Y      Y
Day and Month of T2DM diagnosis unknown
Day of T2DM diagnosis unknown
2.What type 2 diabetes oral medication(s) is the patient currently taking?  Please check all that apply.
Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
Sulfonylureas  chlorpropamide
  glibenclamide or glyburide
  glibornuride
H9X-MC-B021(b) Clini calProtocol Page 102
LY2189265Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
  gliclazide
  glimepi[INVESTIGATOR_14956]
  glipi[INVESTIGATOR_7130]
  gliquidone
  glisoxepi[INVESTIGATOR_5328]
  glyburide micronized 
  glyclopyramide
  glycyclamide or tolhexamide
  met ahexamide
  tolazamide
  other
Meglitinides  met formin
  nateglinide
  repaglinide
  other
DPP -4 Inhibitors  alogliptin benzoate
  linaglipt in
  saxaglipt in
  sitaglipt in
  vildaglipt in                 
H9X-MC-B021(b) Clini calProtocol Page 103
LY2189265Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
  other
SGLT2 Inhibitors  canagliflo zin             
  dapagliflozin                  
  empagliflozin             
  other
Thiazolidinediones
(TZDs or Glitazones)  pi[INVESTIGATOR_051]
  rosiglitazone               
  other
Alpha -glucosidase 
inhibitors  acarbose
  mig litol                         
  other
Combination Pi[INVESTIGATOR_3353]  alogliptin benzoate/met formin 
hydrochloride
  canagliflo zin/met formin 
hydrochloride
  dapagliflozin/met formin
  dapagliflozin propanedio l/metformin 
hydrochloride
  empagliflozin/linaglipt in                
H9X-MC-B021(b) Clini calProtocol Page 104
LY2189265Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
  glimepi[INVESTIGATOR_14956]/pi[INVESTIGATOR_051]
  glimepi[INVESTIGATOR_14956]/rosiglitazone maleate
  met formin/empagliflozin
  met formin/glipi[INVESTIGATOR_7130]
  met formin/glyburide
  met formin/linaglipt in
  met formin/pi[INVESTIGATOR_051]
  met formin/repaglinide
  met formin/rosiglitazone maleate
  met formin/saxaglipt in
  met formin/sitagliptin
  met formin/vildaglipt in
  simvastatin/sitaglipt in phosphate
  other
3.Does the patient currently have any of the following comorbidities?  Please check all that apply.
  Congestive heart failure
H9X-MC-B021(b) Clini calProtocol Page 105
LY2189265  Dement ia 
  Chronic Pulmo nary Disease
  Rheumatologic Disease
  Mild Liver Disease
  Diabetes with chronic co mplications
  Hemiplegia or paraplegia 
  Renal disease
  Any malignancy, including leukemia and lympho ma
  Mo derate or severe liver disease
  Metastatic so lid tumor
  AIDS/HIV
  None
4.Please record the patient’s most recent HbA1c value and the date this value was measured.
Date of HbA1c
measurement HbA1c value
DD/MMM/YYYY ___%
H9X-MC-B021(b) Clini calProtocol Page 106
LY2189265Appendix 23. Protocol Amendment H9X-MC-B021 (b)Summary  Crossover Study 
Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen
Overview
Protocol  H9X -MC-B021 (a)[Crossover Study Comparing the Dulaglut ide (Trulicit y) Pen and the Semaglut ide (Ozempic) Pen ]has 
been amended.  The new protocol is indicated by  [CONTACT_61504] ( b) and will be used to conduct the study in place of any preceding 
versio n of the protocol.
Based on the resul ts from pi[INVESTIGATOR_731751], some scheduling, training, and administrative protocol elements have changed to 
reflect learnings fro m the pi[INVESTIGATOR_799] .  
Changes to the protocol were made for the fo llowing reasons:
Sponsor decisio n to streaml ine study  based on participant feedback
Minor edi torial changes have also been made throughout the document.
The overall changes and rationale for the changes made to this protocol are described in the fo llowing table:
Amendment Summary for Protocol H9X-MC-B021 Amendment (b )
Section # and Name [CONTACT_19523] 2, Synopsis Table 2.1 A break will be ‘offered’ to participants Participants in the pi[INVESTIGATOR_727456] a 
restroom or water break between device trainings. 
The break will be offered to participants, but it will 
be optional.
Section 2, Synopsis Table 2.[ADDRESS_999618] it.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999619] the IFU available to 
read and review du ring the training, so additional 
text was added to help assure clarity on this point.
Section 5.5.4 Overview of study visit procedures 
for the main studyMaximum time for all study procedures was 
added.90 minutes, as specified in the consent form
Sectio n [IP_ADDRESS] Global Preference Item The open ended response to explain reasons for 
device preference was changed from patient 
completed to interviewer completed. The results of the pi[INVESTIGATOR_731752] a clear respon se to 
this question. Participants are better able to 
articulate reasons for preference when speaking 
with the interviewer. Therefore, in the main study, 
the interviewer will ask the participant for the 
reasons for their device preference and record the 
reasons for the participant using quotations marks 
to capture the respondent’s exact words.
10.2 Populations for analysis Video removed Based on results of the pi[INVESTIGATOR_799], the video will 
not be used in the main study.
Appendix 12 Interview and Device Training 
GuidesInterview guides were updated to incorporate 
revisions made during the pi[INVESTIGATOR_799].The interview guides were revised during the pi[INVESTIGATOR_731753], present training 
information clearly, and address issues identified 
during the pi[INVESTIGATOR_799].
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999620] the 
reasons for the participant using quotations marks 
to captur e the respondent’s exact words.
Appendix [ADDRESS_999621] any of the listed 
conditio ns.
H9X-MC-B021(b) Clini calProtocol Page 109
LY2189265Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
The numbering system used for inclusio n and exclusion criteria provides a unique number for 
each cri terion and all ows f or efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardless of whether it is an inclusio n or excl usion cri terion.
2.  Schedule of Activities
Table 2.1. Schedule of A ctivities
ProcedurePi[INVESTIGATOR_42751] :  Conducted 
at 1 US Location1
Approximately n ≈ 10 to 
20Main Phase:  Conducted 
at Approximately 14
Clinical Sites across US2
Approximately n ≈ 290
Screening Study Visit Screening Study Visit
INTERVIEW BREAK 1:  Participant will be given
offered a restroom and water breakX X
OPTIONAL INTERVIEW BREAK 2 X X
3.5.  Methods to Minimize Risks
Training on both study  devices will be provided by [CONTACT_731769] (Eli Lilly IFU 2017; Novo Nordisk IFU 2017).  Training for correct sharps 
handling/disposal is part of the study  training, and no cross contaminat ion is expected due to 
each parti cipant receiving their own device, as well as injecting drug into a practice pad instead 
of themselves.  In order to minimize risk of accidental needle st icks, participants will not recap 
the sem aglut ide needle.  A sharps container will be available to permit participants to remove the 
semagl utide needle and dispose of it immediately, rather than recappi[INVESTIGATOR_731754] .  Parti cipants will be instructed to place the outer needle cap in the sharps container 
once i t is rem oved from the device so they  do not have the temptation to recap, which was found 
to be a potential opportunity  for acci dental  needle sti cks during the pi[INVESTIGATOR_799] .  Study  staff will 
monitor the parti cipant at all times in the room and intervene should a dangerous situation occur.  
Parti cipants will be under di rect supervisio n of the study  interviewer when handling the devices.
5.5.4.  Overview of Study Visit Procedures for the Main Phase
H9X-MC-B021(b) Clini calProtocol Page 110
LY2189265Trained study  interviewers will fo llow the study  Intervi ew and Device Training Guide 
(Appendix 12 ) to standardi ze the presentat ion of devices to participants and ensure that the 
training is clear and not biased in favor of either device.  Based on findings from the pi[INVESTIGATOR_32731], 
the finalized main phase training approach will be conducted with the patients for each device 
including a detailed demo nstrati on by [CONTACT_20679]. (for example , will  include a combinat ion 
of the fo llowing:  detailed demo nstrati on by [CONTACT_20679], presentation of video 
demonstrati ons on tablets or l aptops, and/or independent reading o f the IFU).   The same 
standardized interview approach will be used for all ofthe main phase pat ients.  For each device, 
patients will  be given the IFU and asked to read it.  Then the interviewer will demo nstrate how to 
use the device.   Parti cipants will perform mock i njecti ons on a practi ce pad after being trained in 
the use of each device.  Patients will have access to the IFU during the ent ire training and 
inject ion process.   If the participant does not complete one of the crit ical steps or if the steps are 
completed out of order, the Interview and Device Training Guide ( Appendix 12 ) provi des 
interviewers instructi ons for handling these situat ions.
5.5.[ADDRESS_999622] ion(s) on the practice pad, 
interviewers will co mplete the Interviewer Recording Sheet to document randomizat ion order 
and if the patient was able to com plete both device trainings ( Appendix 15 ).  Next, participants 
will be o ffered an optional sec ond break.   Parti cipants will then be asked to complete 
questionnaires to report their preferences between the [ADDRESS_999623] approximately  60 to 90 minutes including c onsent ing and training 
in device procedures.  The maximum time for all study  procedures is 90 minutes as specified in 
the consent form.   All main phase participants will be remunerated a specified amount between 
$100 and $150 (via Greenphire ClinCard) for thei r time and travel  time to the study  interview.
[IP_ADDRESS] .  Global Preference Item
All participants will complete the Global Preference Item after being trained and using both 
devices ( Appendix 17 ).  Parti cipants will be asked, “ Overall , which device do y ou prefer?”  
Interviewers will then ask Pparti cipants will also be asked to explain why they  selected thei r 
response for Ozempic, Trulicit y, or no preference.  The interviewer will transcribe the 
participant’s response using quotes ation marks to capture the respondent’s exact words.  This 
item The Global Preference Item  was developed specifically  for use in this device preference 
multicenter crossover study .  To hel p parti cipants rem ember the devices more accurately, colored 
images of the devices have been inserted into the questionnaire.
10.2.  Populations for Analyses
For purposes of analysis, the following populat ions are defined:
H9X-MC-B021(b) Clini calProtocol Page 111
LY2189265Population Description
Randomized Participants determined to be eligible and then assigned to one of 2 device 
order groups (50% will be randomized to use the dulaglutide device first, 
while the other half will use the semaglutide device first).  More details about 
randomization for this st udy are provided in Section 7.2.
Evaluable Participants for whom device preference can be evaluated: Randomized 
participants who are exposed to both devices (i.e., participant was shown both 
devices via either video or demonstration, regardless of whether they 
successfully complete the training) and complete the Global Preference Item.
Withdrawn Participants who withdraw from the study before being exposed to both 
devices and completing the Global Preference item.  Details on study 
withdrawal are provided in Section 8.
Appendix 12.  Interview and Device Training Guide
EVA -[ZIP_CODE] Interview and Device Training Guide
(Will be m odified based on findings from the Pi[INVESTIGATOR_42751])
Updated 12Jul2018
I. NECESSARY MATERIALS
11.IFU for Trulicit y
12.IFU for Ozempic
13.Trulicit y Inject ion Pen 
14.Trulicit y Dem onstrati on Pen
15.Ozem pic Inject ion Pen (the real Ozempic Pen will also be used for demonstrations)
16.Extra needles for Ozempic
17.Sharps container (for disposal o f Trulicit y Devices and Ozempic Needles)
18.Inject ion pad
19.Alcoho l wipes
20.Trash can (for pen cap)
21.Non-latex gloves
II. INTERVIEW STEPS
11.Confirm that site has completed In/Ex form
12.Administer informed consent 
13.Com plete Suppl emental  Quest ion S1 
14.Randomization wit h IWRS system to determine which device is first
15.Explain study  to the parti cipant
16.Training and mock inject ion with the fi rst device
17.Com plete dem ographic form
18.Training and mock inject ion with the second device.
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999624] ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
7.The training will be considered complete wh en the pati ent has successfully  performed all  
critical steps listed bel ow and indicated to the trainer that they  are finished (for example, by 
[CONTACT_731796]).  For the time- to-train pat ients, timing will end after 
successful inject ion com pletion at the time patients indicate they  are finished.
8.If the participant does not dispose of the device in the sharps container independent ly, the 
trainer should instruct the participant on device disposal using the provided sharps 
container.
B. Checklist of Critical Steps
Critical StepsFirst 
attemptSecond 
attemptThird 
attemptFourth 
attemptFifth 
attempt
1. Take off base cap □ □ □ □ □
2. Place on inject ion site □ □ □ □ □
3. Unl ock device □ □ □ □ □
4. Press button and ho ld the 
device in place unt il the grey  
plunger is visible.  The 
participant shoul d pause.□ □ □ □ □
5. Remove from inject ion site □ □ □ □ □
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999625] ion process.  If the participant appears to be making an error that could lead to 
self-harm or prevent successful injection (e.g., trying to inject with the cap on), the trainer should 
intervene and stop the injection process.  The error should be explained to the participant and the 
participant shoul d be asked to restart the injection process.
IV. Ozempic Pen
For time -to-train parti cipants, the observer shou ld begin the timer when the training introduction 
is started.  The observer should also complete the TTT Observer Recording Sheet.
A. Device Training
1.Explain the overall training steps and introduce the device to the participant.
2.Open the device box and p lace the IFU in front of the participant.  Explain that the video 
will fo llow along wit h the instructions for use and demonstrate how the device is used. 
3.Show the participant the Ozempic training video, which is based on the IFU.
4.If the participant needs addit ional training, demonstrate the inject ion process using the 
demo device.  Have the participant follow along wit h the steps on the IFU. 
5.Permi t the parti cipant to ask any  quest ions they  may have about the device or IFU.
6.Parti cipant performs m ock inject ion into the inject ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
7.The training will be considered complete when the patient has successfully  performed all  
critical steps lis ted bel ow and indicated to the trainer that they  are finished (for example, by 
[CONTACT_731796]).  For the time- to-train pat ients, timing will end after 
successful inject ion complet ion at the time patients indicate they  are finished.
8.If the participant does not dispose of the device in the sharps container independent ly, the 
trainer should instruct the participant on device disposal using the provided sharps 
container.
B. Checklist of Critical Steps
Critical StepsFirst 
attemptSecond 
attemptThird 
attemptFourth 
attemptFifth 
attempt
1. Pull o ff the pen cap □ □ □ □ □
2. Push the needle straight on to 
the pen.  Turn unt il it is on ti ght.  □ □ □ □ □
H9X-MC-B021(b) Clini calProtocol Page 114
LY21892653. Pull o ff the outer needle cap and 
pull o ff the inner needle cap□ □ □ □ □
4. Turn the dose selector until the 
dose counter shows the flow check 
symbo l□ □ □ □ □
5. Press and hold the dose button 
until the dose counter shows 0 and 
a drop of Ozempic appears at the 
needle t ip□ □ □ □ □
6. If the drop does not appear on 
the first attempt, repeat flow check 
until a drop appears (as needed).□ □ □ □ □
7. Sel ect y our dose.  Continue 
turning the dose selector un til the 
dose counter shows 0.25□ □ □ □ □
8. Insert the needle in the pad □ □ □ □ □
9. Press and ho ld down the dose 
button until the dose counter 
shows 0□ □ □ □ □
10. Sl owly  count to 6 
(operati onally:  patient pauses 
after pressing inject ion button). □ □ □ □ □
11. Remove the needle fro m the 
pad□ □ □ □ □
12. Remove the needle (capped or 
uncapped)□ □ □ □ □
C. Retraining
If the first injection attempt is not successful, the participant should be retrained on the critical 
steps that they  missed or performed incorrectly.  The participant will have to repeat all or some 
of the inject ion process.  If the participant appears to be ma king an error that could lead to self -
harm or prevent successful inject ion (e.g., trying to inject with the cap on), the trainer should 
intervene and stop the injection process.  The error should be explained to the participant and the 
participant shoul d be asked to restart the injection process.
Interview Guide
I. MATERIALS
1.IFU for Trulicit y
2.IFU for Ozempic
3.Trulicit y Inject ion Pen 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999626] ion Pens (one for demonstration and one for participant use)
6.Sharps container (for disposal o f Trulicit y Devices and Ozempic Needles)
7.Inject ion pad
8.Alcoho l wipes
9.Trash can (for pen cap)
10.Non-latex gloves
II. INTERVIEW STEPS
1.Confirm the in/ex form has been co mpleted
2.Inform ed consent 
3.Com plete Suppl emental  Quest ion S1
4.Randomization wit h IWRS system to determine which device is first
5.Explain study  to the parti cipant
6.First Device: Training and Mock Inject ion
7.Com plete dem ographic form
8.Second Device: Training and Mock Inject ion
9.Com plete Intervi ewer Recording Sheet
10.Com plete questi onnaires about devi ce preferences and Supplemental Quest ions S2 and 
S3
STEP 1. CONFIRM IN/EX FORM HAS BEEN COMPLETED
Review the site- completed in/ex form for the participant to confirm eligibilit y.  
This form  shoul d be provi ded to y ou by  [CONTACT_779], and it should already be co mpleted prior 
to the interview. 
STEP 2. INFORMED CONSENT
Review the consent form wit h the participant and confirm co mprehensio n.  
Provi de the parti cipant wi th opportuni ty to answer questions before signing.
Ask the participant to sign two copi[INVESTIGATOR_731755] .  
Countersign the forms and provide a copy  to the parti cipant. 
STEP 3. COMPLETE SUPPLEMENTAL QUESTION S1
Ask the participant to independently co mplete this question: “Please complete this 
question, and let me know when y ou are finished.” 
H9X-MC-B021(b) Clini calProtocol Page 116
LY2189265STEP 4. RANDOMIZATION WITH IWRS SYSTEM
Com plete the randomizat ion process to determine the order of device training for the 
participant. 
Record the order on the Interviewer Recording Sheet. 
STEP 5. EXPLAIN THE STUDY TO THE PARTICIPANT
“You will be trained to use two devices for inject ing medicat ion for type 2 di abetes.” 
“For each device, I will walk y ou through the steps for using each d evice and 
demonstrate the steps for y ou.  Then, y ou will use the device to administer an inject ion 
into an inject ion pad.” 
“After y ou have had a chance to use both devices, I will ask y ou to com plete som e 
questionnaires that ask about y our preference betw een the devices.” 
“Do not inject medication into yourself.  You will only be injecting into the injection 
pad.”  
“Please handle the devices carefully  to avoi d accident ly sticking y ourself wi th the needle.  
If you appear to be handling the device incorrec tly, I will try  to correct y ou so y ou do not 
accidently st ick yourself wit h the needle.” 
STEP 6. FIRST DEVICE TRAINING
Follow the Trulicit y Training Guide or the Ozempic Training Guide based on the randomizat ion 
order for the participant. 
STEP 7. DEMOGRAPHIC FORM
“Please complete this form.”
STEP 8. SECOND DEVICE TRAINING
Follow the Trulicit y Training Guide or the Ozempic Training Guide based on the randomizat ion 
order for the participant. 
STEP 9. COMPLETE INTERVIEWER RECORDING SHEET
The interviewer completes the interviewer recording sheet to document order of device training 
and co mpletion status. 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999627] the participant to com plete questi onnai res on device preference and supplemental 
questions S2 and S3.
Ozempic Training Guide
A. Time to Train
The observer should co mplete the TTT Observer Recording Sheet.
a.Start of training (i.e., after reading the IFU)
b.The parti cipant pi[INVESTIGATOR_731745]. 
c.The parti cipant successfully  injects the m edicat ion into the inject ion pad and removes the 
needle/device from the pad. 
d.The Ozempic pen is recapped with the pen cap (the inner needle cap and outer needle cap 
shoul d not be pl aced back on the pen) . 
e.The pa rticipant has com pleted the inject ion and finished asking questions.  Participants 
comments/opi[INVESTIGATOR_731747] a question. 
B. Safety Procedures
If the participant appears to be making an error that could lead to self- harm, the trainer should 
immediately  intervene and stop the inject ion process.
C. Introduction
Introduce the device and training steps.
“Now, you will  learn to use an inject ion device.”
“When y ou fe el comf ortabl e with the procedures for using the device, y ou will use the 
device to perform a mock inject ion into the injection pad.”
“You should NOT use this device to inject y ourself.  You will only  be inject ing 
medicat ion into this pad.”
“This is t he Ozempic device.  This device is used to administer medicat ion once a week, 
and y ou woul d typi[INVESTIGATOR_153795] i t at hom e.”(Show  the device to the participant .)  
D. Device Training
1. Open the device box and place the IFU in front of the participant. 
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999628] the parti cipant to “Pl ease read the Instructions for Use and let me know when y ou are 
finished.  After y ou are done reading, I will demo nstrate all o f these steps for y ou in detail.  
You can al so refer back to this document throughout the interview as muc h as y ou want.”
3.Dem onstrate the injection process using the demo device. 
1.“The Ozempic device is a prefilled dial-a -dose pen .  You can select doses of 0.[ADDRESS_999629] ion today .”
2.“The needles for this device are enclo sed in the package.” 
3.“Always use a new needle for each injection .”
4.Device parts
a.“This is the pen cap .”
b.“This is the pen window .” 
c.“This is the dose counter and dose pointer .” 
d.“This is the dose sel ector and the dose button .”
e.“When y ou turn the dose selector, y ou will see the flow check symbol  and the dashed 
line to gui de to y our dose ( turn dose selector to show  these symbols ).  The flow check 
symbo l comes right after the zero .”
f.“The needle has an outer needle cap, inner needle cap, needle, and paper tab. ”
5.Step 1: Prepare your pen with a new needle
a.“If you were inject ing, y ou woul d begin by  [CONTACT_14390] y our hands with soap and water. 
Since y ou are inject ing a pad today, you do not need to wash your hands this time. ”
b.“The next step is to check the name [CONTACT_731805] m ake sure that 
it contains Ozempic.”
c.“Then pull off the cap .”
d.“Check that the Ozempic in your pen is clear and colorless . Look through the pen 
window.  If the Ozempic is cloudy, do n ot use the pen.”
e.“Take a new needle , and tear off the paper tab.”
H9X-MC-B021(b) Clini calProtocol Page 119
LY2189265f.“Push the needle straight on to the pen.  Turn until it is on tight .”
g.“Pull off the outer needle cap .  You can put it in the sharps container .”
h.“Pull off the inner needle cap , and throw i t away .”
6.Step 2: Check the Ozempic flow with each new pen
a.“Check the Ozempic flo w before y our first injection with each new pen.”
b.“Turn the dose selector until the dose counter shows the flow check symbol .”
c.“Hold the pen wit h the needle po inting up.  Press and hold in the dose button until 
the dose counter shows 0.  The [ADDRESS_999630] fro m me.”
d.“If no drop appears , repeat these flow check steps up to six more times.  Do not use 
the pen if a drop of Ozempic st ill does not appear.”
7.Step 3: Select your dose
a.“Turn the dose selector until the dose counter shows your dose ( 0.25 mg) .  If you 
select the wrong dose, y ou can turn the dose selector forward or backwards to the 
correct dose.”
8.Step 4. Inject your dose
a.“Choose y our inject ion site.”
b.“Insert the needle into your skin [injection pad ].”
c.“Make sure you can see the dose counter .  Do not cover i t with your fingers.  This 
could stop the inject ion.”
d.“Press and hold down the dose button until the dose counter shows [ADDRESS_999631] 
line up with the dose pointer.  You may then hear or feel a click.”
e.“Keep the needle in your s kin[injection pad] after the dose counter has returned to 
0 and count slowly to 6 .”
f.“If the needle is removed earlier, y ou m ay see a stream  of Ozempic coming from the 
needle t ip.  If this happens, the full dose will not be delivered.”
g.“Remove the needle from your skin [injection pad ].”
H9X-MC-B021(b) Clini calProtocol Page 120
LY21892659.Step 5. After your injection
a.“Carefully twist the needle off of the pen.   Since we have a sharps container, 
please do not put the needle caps back on the needle to avoid needle st icks.”
b.“Place the needle in a sharps container right away .”
c.“Put the pen cap on your pen after each use to protect Ozempic fro m light.”
4.Permi t the parti cipant to ask any  quest ions they  may have about the device or IFU.
“Do y ou have any quest ions about the steps invo lved in the inject ion pro cess?”
“Do y ou feel ready  to administer the m ock inject ion?Is there any thing y ou woul d like to 
review before trying it ?”
When the patient is ready: “I will leave the instructio ns for use here, and y ou can refer to 
them as m uch as y ou like while y ou go t hrough the injection process.  Please take all the 
time y ou need.”
5.Parti cipant performs m ock inject ion into the inject ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
6.The m ock inject ion will be cons idered complete when the patient has successfully performed 
all critical steps listed below and recapped the pen.  
7. If the participant is struggling to remove the needle and appears to be putting themselves at 
risk of an accidental needle st ick, the interviewer should vo lunteer to rem ove the needle for 
them. 
“Woul d you like me to rem ove the needle for y ou?”
If the int erviewer removes the needle, this should be recorded on the Interviewer Recording 
Sheet. 
8.If the participant does not dispose of the needle in the sharps container independent ly, the 
trainer should instruct the participant on disposal using the provided s harps container.
“Please place the needle in the sharps container.”
9.Ask the participant if they have any  questi ons, and answer them.  The training is complete 
when there are no further questions. 
“Do y ou have any quest ions?”
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999632] 
attemptFourth 
attemptFifth 
attempt
1.Pull o ff the pen cap □ □ □ □ □
2.Push the needle straight on to 
the pen.  Turn unt il it is on 
tight.  □ □ □ □ □
3.Pull o ff the outer needl e cap 
and pull o ff the inner needle 
cap□ □ □ □ □
4.Turn the dose selector until the 
dose counter shows the flow 
check symbo l□ □ □ □ □
5.Press and ho ld the dose button 
until the dose counter shows 0 
and a drop of Ozempic appears 
at the needle ti p□ □ □ □ □
6.6. If the drop does not appear 
on the first attempt, repeat flow 
check unt il a drop appears ( up 
to 6 times ).□ □ □ □ □
7.Select y our dose. Continue 
turning the dose selector un til 
the dose counter shows 0.25□ □ □ □ □
8.Insert the needle in the pad □ □ □ □ □
9.Press and ho ld down the dose 
button until the dose counter 
shows 0□ □ □ □ □
10.Slowly  count to 6 
(operati onally: pat ient pauses 
after pressing inject ion button). □ □ □ □ □
11.11. Remove the needle fro m the 
pad□ □ □ □ □
12.Remove the needle from the 
pen (capped or uncapped)□ □ □ □ □

H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999633].“It looks like the inner cap is still on.  Could you remove the inner cap before checking the 
flow?”
H9X-MC-B021(b) Clini calProtocol Page 123
LY2189265Trulicity Training Guide
A. Time to Train
The observer should co mplete the TTT Observer Recording Sheet.
a. Start of training (i.e., after reading the IFU)
b. The participant pi[INVESTIGATOR_731745]. 
c. The participant successfully injects the medicat ion in to the inject ion pad and removes the 
needle/device from the pad. 
d. The Trulicit y pen is dropped into the sharps container.
e. The participant has co mpleted the inject ion and finished asking quest ions.  Participants 
comments/opi[INVESTIGATOR_731756] r com pleting the inject ion will not be included unless 
the participant asks a quest ion. 
B. Safety Procedures
If the participant appears to be making an error that could lead to self -harm, the trainer should 
immediately  intervene and stop the inject ion process.
C. Introduction
Introduce the device and training steps.
“Now, you will  learn to use an inject ion device.”   
“When you feel co mfortable with the procedures for using the device, y ou will use the 
device to perform a mock inject ion into the injection pad.” 
“You should NOT use this device to inject y ourself.  You will only  be inject ing 
medicat ion into this pad.”
“This is the Trulicit y device.  Thi s device is used to administer medicat ion once a week, 
and y ou woul d typi[INVESTIGATOR_153795] i t at hom e.”(Show  the device to the participant .)  
D. Device Training
1.Open the device box and place the IFU in front of the participant.
2.Instruct the participant to “Please read the Instructions for Use and let me know when y ou are 
finished.  After y ou are done reading, I will demo nstrate all o f these steps for y ou in detail.  
You can al so refer back to this document throughout the interview as much as y ou want.”
3.Dem onstrate the injection process using the demo device. 
1.Before you get started
a.“Check the pen label to make sure y ou have the ri ght m edicine and i t has not 
expi[INVESTIGATOR_5697].”
H9X-MC-B021(b) Clini calProtocol Page 124
LY2189265b.“Inspect the pen to make sure i t is not dam aged”
c.“Inspect the m edicine to make sure i t is not cl oudy or di scolored, and it should not 
have particles in it.”
d.“If you were inject ing yourself, y ou woul d then wash y our hands .  Since y ou are 
inject ing a pad today , you do not need to wash y our hands this ti me.”
e.“If you were inject ing yourself, y ou woul d select an injection site .  Today , you will 
inject into this injection pad and NOT into y our body .” 
2.Device parts
a.“At the top of the device, there is a green inject ion button .”
b.“Beneath that is a lock ring, and an indicator which lines up with the lock and unlock 
symbo ls.”
c.“Down here y ou can see the m edicine .”
d.“At the bottom, y ou can see the clear base and the base cap .”
e.“The needle is inside the device.”
3. Steps for injection
a.Uncappi[INVESTIGATOR_731748]. 
i)“You woul d first m ake sure the pen is locked ” 
ii)“Then pull the base cap straight off and throw i t away  in the trash”. 
iii)“Do not put the base cap back on –this coul d damage the needle.”
b.Second, place the base on the inject ion site and unlock the device
i)“You woul d place the cl ear base flat and firmly against y our skin (or in this case, 
the inject ion pad).” 
ii)“Unlockby [CONTACT_480767]”.
c.Third, administer the inject ion
H9X-MC-B021(b) Clini calProtocol Page 125
LY2189265i)“You woul d press and ho ld the green inject ion button .  You will hear a loud 
click.” 
ii)“When y ou press the button, the medicat ion is injected .”
iii)“Continue to hold the clear base firmly against the pad until y ou hear a second 
click .  This happens when the needle starts retracting in about 5 –10 seconds.  My 
demo device may  be slower than the actual device you use, so listen closely for 
the click on y our devi ce.” 
iv)“Then remove the pen from your skin [injection pad ].”
v)“You will know the inject ion is co mplete when the gray  plunger i s visible.” 
d.The final step is disposing of the pen. 
i)“Put y our used pen in the sharps disposal container right away  after use”.
4.Permi t the parti cipant to ask any  quest ions they  may have about the device or IFU.
“Do y ou have any quest ionsabout the steps invo lved in the inject ion process?”
“Do y ou feel read y to administer the m ock inject ion?Is there any thing y ou woul d like to 
review before trying it ?”
When the patient is ready: “I will leave the instructio ns for use here , and y ou can refer to 
them as m uch as y ou like while y ou go through the injection proc ess.  Please take all the 
time y ou need.”
5.Parti cipant performs m ock inject ion into the inject ion pad while trainer observes and 
evaluates injection success based on the crit ical steps listed bel ow.
6.The m ock inject ion will be considered complete when the patient has successfully performed 
all critical steps listed below and placed the device in the sharps container.  
7.If the participant does not dispose of the device in the sharps container independent ly, the 
trainer should instruct the participant on device disposal using the provided sharps container. 
“Please place the pen in the sharps container.”
8.Ask the participant if they have any  questi ons, and answer them.  The training is complete 
when there are no further questions.
“Do y ou have any quest ions?”
H9X-MC-B021(b) Clini calProtocol Page [ADDRESS_999634] 
attemptFourth 
attemptFifth 
attempt
1. Take off base cap □ □ □ □ □
2. Place on inject ion site □ □ □ □ □
3. Unl ock device □ □ □ □ □
4. Press button and ho ld the 
device in place unt il the grey  
plunger is visible. The 
participant shoul d pause. □ □ □ □ □
5. Remove from inject ion site □ □ □ □ □
F. Retraining (if necessary)
If the crit ical steps are not performed correctly on the first attempt, the participant should be 
retrained on crit ical steps that were missed or performed incorrectly .  The parti cipant m ay have 
to repeat all or some of the inject ion process.  The error sh ould be explained to the participant 
and the participant should be asked to make the correction and cont inue the inject ion process. 
If the participant is making a mistake during the inject ion, you can call  their attenti on to the 
mistake so that he or she can continue the injection correctly.  For example, if the participant is 
trying to press the inject ion button without unlocking the device, tell the participant to unlock it.  
“It looks like the device is st ill locked.  Can y ou unl ock i t before inject ing?”
Appendix 13.  Time -to-Train (TTT) Observer Recording Sheet
TTT Observer Recording Sheet
(Will be m odified based on findings from the Pi[INVESTIGATOR_42751])
To be com pleted by [CONTACT_731795]:
1. Ozempic     Ozempic Device        Trulicity Device
1a. Start time of training introduction (i.e., after reading the IFU ): 0:00
1b. Start time of participant performing mock injection(s):  ______:______ 
1c. End time of successfully administered mock injection (i.e., withdrawal of needle/device from 
injection pad):  ______:______
1d. End time of mock injection procedures (Ozem pic = recappi[INVESTIGATOR_731748]): ______:______
H9X-MC-B021(b) Clini calProtocol Page 127
LY21892651e. End time of training, including all procedures and questions:  ______:______
Num ber of interventions: _______
Key Steps of Training For Device Used FirstCheck If 
Not 
Applicable
1a. Start time of training introduction:  ______:______:______ am/pm
1b. Finished time of training introduction:  ______:______:______ am/pm
1c. Start time of training video:  ______:_ _____:______ am/pm
1d. Finished time of training video:  ______:______:______ am/pm
1e. Start time of training and questions after video:  ______:______:______ am/pm
1f. End time of training and questions after training:  ______:______:______ am/pm
1g. Start time of participant performing mock injection(s):  ______:______:______ 
am/pm
1h. End time of participant performing mock injection(s):  ______:______:______ 
am/pm
1i. Start time of answering remaining questions: ______:______:______ am/pm
1j.End time of answering remaining questions: ______:______:______ am/pm
2. Trulicity     Ozempic Device        Trulicity Device
2a. Start time of training introduction (i.e., after reading the IFU ): 0:00
2b. Start time of participant performing mock injection(s):  ______:______ 
2c. End time of successfully administered mock injection (i.e., withdrawal of needle/device from 
injection pad):  ______:______
2d. End time of mock injection procedures (Trulicity = disposing of the pen in the sharps 
contai ner): ______:______
2e. End time of training, including all procedures and questions:  ______:______
Num ber of interventions: _______
Key Steps of Training For Device Used SecondCheck If 
Not 
Applicable
H9X-MC-B021(b) Clini calProtocol Page 128
LY21892652a. Start time of training introduction:  _____ _:______:______ am/pm
2b. Finished time of training introduction:  ______:______:______ am/pm
2c. Start time of training video:  ______:______:______ am/pm
2d. Finished time of training video:  ______:______:______ am/pm
2e. Start time of training and questions after video:  ______:______:______ am/pm
2f. End time of training and questions after training:  ______:______:______ am/pm
2g. Start time of participant performing mock injection(s):  ______:______:______ 
am/pm
2h. End time of participant performing mock injection(s):  ______:______:______ 
am/pm
2i. Start time of answering remaining questions: ______:______:______ am/pm
2j. End time of answering remaining questions: ______:______:______ am/pm
Appendix 14.  Demographic Form
Demographic Form –Participant Completed
1.  What is y our age?
2.  What is y our gender? 1  Male   2  Female
3a.  What is y our ethnic background?
1  Hispanic or Latino
2  Not Hispanic or Latino
3  Not applicable
3b.  What is y our raci al background? ( Please check all that apply )
1  Amer ican Indian or Alaska Nat ive
2  Asian
3  Black or African American
4  Native Hawaiian or Other Pacific Islander
5  Whit e
6  Other:  
4.  What is y our m arital status?
1  Single
2  Married
3  Divorced
4  Separated
H9X-MC-B021(b) Clini calProtocol Page 129
LY21892655  Widowed
6  Other:  _____________
5.  How would y ou describe y our em ployment status? (Please ti ck all boxes that apply )
  Full -time work
  Part-time work
  Homemaker/housewife
  Student
  Unemplo yed
  Stay-at-home parent
  Retired
  Disabled
  Other:  ______________________
7.What i s the highest level of educat ion you have completed? ( Please check only one )
1  Elementary /primary school
2  Secondary /high school
3  Some college
4  College degree
5  Postgraduate degree
6  Other:  ______________________________________
7.  Have y ou had any  of the f ollowing healt h conditi ons? (Pl ease t ick/check all boxes that apply )
  Ang ina
  Arthritis
  Cancer 
  Chronic obstructive pulmonary disease/emphysema
  Heart attack or heart disease
  Hypertensio n 
  Stroke
  Depression
  Other mental healt h condit ions (please specify):  ______________________
  Other health condit ions (pl ease specify ):  ________________________________
  None
Appendix 15.  Inter viewer Recording Sheet
Interviewer Recording Sheet
(May be modified based on findings from the Pi[INVESTIGATOR_42751])
H9X-MC-B021(b) Clini calProtocol Page 130
LY2189265To be completed by [CONTACT_20679]:
1. Device Randomized to First Training:     Ozem pic Device        Trulicit y Device
  Participant completed training for first device
  Participant com pleted training, but required interviewer assistance to remove the needle 
(Ozem pic only)
  Participant was exposed to this device but did not complete training.  Please explain below :
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
2. Device Randomized to Second Training:     Ozem pic Device        Trulicit y Device
  Participant completes training for second device
  Participant com pleted training, but required interviewer assistance to remove the needle 
(Ozem pic only)
Appendix 17.  Global Preference Item
To be completed by [CONTACT_55473]:
3.Overall, which device do you prefer?
  Ozempic   Trulicity   No Preference
4.Please explain your preference indicated above in Item 1.
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

H9X-MC-B021(b) Clini calProtocol Page 131
LY2189265To be completed by [CONTACT_86296]:
5.Please explain y our preference indicated in Item 1 on the Global Preference Questi onnai re 
(interviewer to record reasons for device preference provided by [CONTACT_238519], provide 
quotes with quotations marks and write neat ly):
______________________________________________________________________________
_____________ _________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
________________________________ ______________________________________________
Appendix 22.  Clinical Information Form
Clinical Information Form –Site Completed
Instructions:  Please com plete the following questio ns for eligible pat ients.
5.When was the patient diagnosed with T2DM?  
If the day  and m onth are unknown, please report the y ear of di agnosis, and check the box “Day 
and Month of T2DM diagnosis unknown”.
If day is unknown, please report month and year of diagnosis, and check the box “Day  of T2DM 
diagnosis unknown”.
   
                                
                           MD MD     DM    DM   M     Y     Y       Y      Y
Day and Month of T2DM diagnosis unknown
Day of T2DM diagnosis unknown
H9X-MC-B021(b) Clini calProtocol Page 132
LY21892656.What type 2 diabetes oral medication(s) is the patient currently taking?  Please check 
all that apply.
Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
Sulfonylureas  chlorpropamide
  glibenclamide or glyburide
  glibornuride
  gliclazide
  glimepi[INVESTIGATOR_14956]
  glipi[INVESTIGATOR_7130]
  gliquidone
  glisoxepi[INVESTIGATOR_5328]
  glyburide micronized 
  glyclopyramide
  glycyclamide or tolhexamide
  met ahexamide
  tolazamide
  other
Meglitinides  met formin
  nateglinide
  repaglinide
  other
DPP -4 Inhibitors  alogliptin benzoate
  linaglipt in
  saxaglipt in
  sitaglipt in
  vildaglipt in                 
  other
SGLT2 Inhibitors  canagliflo zin             
  dapagliflozin                  
H9X-MC-B021(b) Clini calProtocol Page 133
LY2189265Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
  empagliflozin             
  other
Thiazolidinediones
(TZDs or Glitazones)  pi[INVESTIGATOR_051]
  rosiglitazone               
  other
Alpha -glucosidase 
inhibitors  acarbose
  mig litol                         
  other
Combination Pi[INVESTIGATOR_3353]  alogliptin benzoate/met formin 
hydrochloride
  canagliflo zin/met formin 
hydrochloride
  dapagliflozin/met formin
  dapagliflozin propanedio l/metformin 
hydrochloride
  empagliflozin/linaglipt in                
  glimepi[INVESTIGATOR_14956]/pi[INVESTIGATOR_051]
  glimepi[INVESTIGATOR_14956]/rosiglitazone maleate
  met formin/empagliflozin
  met formin/glipi[INVESTIGATOR_7130]
  met formin/glyburide
  met formin/linaglipt in
  met formin/pi[INVESTIGATOR_051]
  met formin/repaglinide
  met formin/rosiglitazone maleate
  met formin/saxaglipt in
H9X-MC-B021(b) Clini calProtocol Page 134
LY2189265Oral ClassOral Medication Options
(select all that apply)Estimated Start Date of 
Oral T2DM Medication
(MM M/YYYY)
  met formin/sitagliptin
  met formin/vildaglipt in
  simvastatin/sitaglipt in phosphate
  other
7.Does the patient currently have any of the following comorbidities?  Please check all 
that apply.
  Congestive heart failure
  Dement ia 
  Chronic Pulmo nary Disease
  Rheumatologic Disease
  Mild Liver Disease
  Diabetes with chronic co mplications
  Hemiplegia or paraplegia 
  Renal disease
  Any malignancy, including leukemia and lympho ma
  Mo derate or severe liver disease
  Metastatic so lid tumor
  AIDS/HIV
  None
8. Please record the patient’s most recent HbA1c value and the date this value was 
measured.
Date of HbA1c
measurement HbA1c value
MMDD/ DDMMM /YYYY ___%